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A number of canine diseases are associated with an increased risk of thrombo-embolic disease at the 
population level. These include common conditions such as immune-mediated haemolytic anaemia 
(IMHA), protein-losing nephropathies (PLN), and protein-losing enteropathies (PLE). At present there 
is no reliable way of predicting which individual patients are at risk of thrombosis, nor do we know 
whether the risk to an individual remains constant over time or fluctuates throughout the course of 
their disease. One of the mechanisms implicated in prothrombotic states is increased platelet 
activation. There are several ways of measuring platelet activation, which can be grouped into two 
main categories: platelet function assays and markers of platelet activation. These platelet activation 
markers can either be molecules expressed on the platelet surface or substances secreted when 
platelets are activated. Thromboxane A2 is one such substance. Serum levels of Thromboxane A2 can 
be indirectly assessed via measurement of its metabolites in urine, including urinary 11-
dehydrothromboxane B2 (u-11dTXB). In humans, urine thromboxanes are used as biomarkers of 
thrombotic risk in several situations. 
The aims of this study were threefold. Firstly, to assess whether urine thromboxanes are increased in 
dogs with IMHA, PLN and PLE. Secondly, to assess whether urine thromboxanes correlate with 
markers of disease severity, survival, or incidence of thrombosis in dogs with IMHA. And finally, to 
describe the change in urine thromboxane levels over the course of treatment of dogs with IMHA.  
In this thesis I have shown that the u11-dTXB:Cr is increased in dogs with IMHA and PLE compared to 
healthy controls. I found no evidence of an association between u11-dTXB:Cr and markers of disease 
severity, survival or incidence of thrombosis in the subset of dogs with IMHA. The increase in u11-
dTXB:Cr compared to healthy dogs was sustained over the first 6 weeks of treatment in the surviving 
dogs with IMHA. These findings have added to our knowledge of urinary thromboxanes as potential 
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1  Introduction 
Thrombotic disease, in which pathological blood clots form and obstruct blood flow to normal tissues, 
is a major cause of morbidity and mortality in human and veterinary patients. In human medicine, 
ischaemic cardiac disease due to atherosclerosis is the leading cause of death in the UK, and in 2010 
cost the NHS an estimated £7,880 million1. Thrombosis is less common in dogs than in people, 
however there are number of disease states with known predispositions to thromboembolic 
complications. These well recognised prothrombotic diseases include immune-mediated haemolytic 
anaemia (IMHA), a condition involving destruction of red blood cells, protein losing enteropathies 
(PLE) such as inflammatory bowel disease, and conditions involving renal protein loss collectively 
known as protein losing nephropathies (PLN) (Goggs et al., 2019; Williams et al., 2017). It is likely that 
different pathophysiological mechanisms underly thrombosis in these different disease states, and 
also potentially between different individuals with the same disease. The three commonest types of 
thrombus in dogs are pulmonary thromboembolism (PTE), aortic thrombi (ATE), and thrombi of the 
brain causing neurological signs. Pulmonary thrombi cause obstruction of the pulmonary arteries, 
generalised hypoxia, respiratory distress, and can cause acute sudden death. Aortic thrombi tend to 
obstruct blood flow to the hindlegs and cause weakness or paralysis. While there are several 
veterinary studies identifying disease states that carry a risk of thrombosis, we do not currently have 
a means of establishing the level of risk in an individual patient. In a research setting, there are a 
number of ways of measuring platelet activation and hypercoagulability, but very few of these are 
easily available in the clinic. In an ideal world, we would be able to quantify the risk of thrombosis in 
an individual patient by means of a biomarker that is easily measured and minimally invasive to 
patients. In the human field, urinary thromboxanes have been widely investigated as markers of 
platelet activation and have shown promise as measures of thrombotic risk. To date, however, urinary 
thromboxanes have been only minimally investigated in veterinary patients.  
Thus, the aims of this study were threefold. Firstly, to evaluate whether urinary thromboxanes are 
increased in dogs with three commonly seen prothrombotic conditions; IMHA, PLN and PLE. Secondly, 
since clinically we see the highest frequency of thrombosis in IMHA, to evaluate for any association 
between urinary thromboxane levels and disease severity, survival, or incidence of thrombosis. And 
finally, since the duration over which dogs with IMHA on treatment remain prothrombotic is unknown, 
to describe the pattern of urinary thromboxane levels in surviving dogs over the first 6 weeks of 
treatment. 
 
1 NICE Clinical guideline [CG181] Cardiovascular disease: risk assessment and reduction, including lipid 
modification Published date: July 2014 Last updated: September 2016 
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1.1 Normal Haemostasis 
Haemostasis is the essential process by which haemorrhage from a vessel wall is stopped. The classical 
model of haemostasis separates the formation of a blood clot into three stages; Primary haemostasis 
in which an initial platelet plug is formed, secondary haemostasis in which a series of enzymatic 
reactions within the plasma leads to generation of fibrin to stabilise the platelet plug, and finally 
fibrinolysis in which the clot is dissolved once vessel healing is complete. While for ease these stages 
are classically thought of as occurring sequentially, in reality they occur simultaneously, with a fine 
balance between procoagulant, anticoagulant and fibrinolytic factors controlling normal clot 
formation. In recent years our advancing understanding of this process has led to increased 
appreciation of the complex interactions between the blood-borne factors and the surfaces upon 
which clotting occurs, including both blood vessels and a variety of blood-borne cells and particles. 
This has resulted in development of a new ‘cell-based’ model of haemostasis (Hoffman and Monroe, 
2001; Smith, 2009). However the classical three part model of primary, secondary and tertiary 
haemostasis remains a useful starting point, as it underpins many of the clinically available tests of 
haemostasis (Weiss et al., 2010). 
1.1.1 Primary Haemostasis 
Primary haemostasis is defined as the formation of a loose platelet plug, which physiologically 
normally occurs at a site of endothelial injury. Certain pathological changes can also trigger primary 
haemostasis, leading to abnormal clot formation known as thrombosis. Primary haemostasis has three 
key stages; platelet adhesion, platelet activation and platelet aggregation. Although these are most 
easily thought of as occurring sequentially in an individual platelet, physiologically they will be 
occurring simultaneously, with the number of platelets involved governing whether a clot forms 
successfully. As well as the platelets themselves, von Willebrand factor released by endothelial cells, 
extracellular matrix proteins such as collagen, and plasma fibrinogen are all essential to primary 
haemostasis (McMichael, 2005; Weiss et al., 2010).  
1.1.1.1 Platelet adhesion 
Primary haemostasis is initiated when damage to the vascular endothelium results in two changes; 
exposure of subendothelial matrix proteins such as collagen to which platelets can adhere, and 
secretion of soluble mediators that contribute to platelet activation (McMichael, 2005; Smith, 2009; 
Weiss et al., 2010). In their circulating resting state, platelets constitutively express several surface 
receptors. These receptors include a family of integrins and glycoproteins that are key to platelet 
adhesion, and several families of receptors for soluble ligands such as prostacyclins and thromboxanes 
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which are key to platelet activation (Table 1). In their resting state, many of these receptors are only 
expressed at low levels, with greater numbers of receptors being trafficked to the cell surface after 
platelets have been activated. Some receptors also change to a higher affinity binding state once they 
have been activated, which helps to form more stable connections as clots mature (Bye et al., 2016; 
Goggs and Poole, 2012). Resting platelets are also continuously exposed to nitrous oxide and 
prostacyclins excreted by healthy vascular endothelium, which act on platelets to maintain them in 
their inactive state (Cheng et al., 2002). Once collagen and matrix proteins such as tissue factor (TF) 
have been exposed by endothelial damage, platelets can start to bind to the site of injury using these 
constitutively expressed surface receptors. The key receptors involved at this stage are glycoprotein 
VI and integrin GPIa-IIa (α2β1), both of which bind to collagen directly. Damaged endothelial cells also 
release von Willebrand factor (vWF) into the plasma and into the local subendothelial matrix. Platelets 
additionally bind to vWF via their surface receptors GPIIb-IIIa(αIIbβIII) and GPIb-IX-V so that vWF acts 
as an anchor between the platelets and the subendothelial matrix (Bye et al., 2016; Goggs and Poole, 
2012). The importance of this second indirect binding via vWF is greater in arteries than in the small 
capillaries and veins, as the higher flow rate of arterial blood makes it harder for adequate direct 
binding to collagen to occur (Lenting et al., 2012). Binding to these receptors also activates 
intracellular signalling pathways that start to initiate platelet activation.  
 
Table 1: Selected platelet surface receptors 
Receptor Other names Main function Main ligand 
glycoprotein VI   direct adhesion collagen 
integrin GPIa-IIa α2β1 integrin direct adhesion collagen 
glycoprotein Ib-IX-V   indirect adhesion via vWF vWF 







  platelet activation TXA2 
P2Y receptor family   platelet activation ADP 
thrombin receptor 
family 
PAR  platelet activation thrombin 
P-selectin CD62P platelet aggregation 
platelet-leucocyte interactions 
PSGL-1 
Abbreviations: PAR, protease-activated receptor; vWF, von Willebrand factor; TXA2, thromboxane A2; ADP, 
adenosine diphosphate; PSGL-1, P-selectin glycoprotein ligand-1 




1.1.1.2 Platelet activation 
Activation of platelets results in structural change and release of preformed surface receptors, 
coagulation factors and soluble molecules from cytosolic granules, all of which act together to recruit 
further platelets to the forming clot to cover the entire endothelial injury, and to stabilise the binding 
between the various clot components (Weiss et al., 2010). There are two groups of triggers for platelet 
activation; platelet adhesion and activation of surface integrin receptors as outlined above, and the 
action of soluble mediators. These mediators are excreted both by damaged endothelial cells and 
other nearby platelets that are already activated, and include ADP, thromboxane, adrenaline, 
prostaglandins, thromboglobulins, platelet factors, and thrombin. There are a number of different 
types of receptor for each of these mediators (Table 1), with each receptor linked to numerous 
interacting intracellular pathways. Two of the key ones are the phospholipase C pathway and the 
phospholipase A2 pathway. The main results of the agonist pathways are an increase in intracellular 
calcium, or a decrease in cyclic AMP activity, which in turn lead to numerous end effects. Broadly 
speaking there are five key outcomes of platelet activation; structural change of the platelet; 
degranulation; alteration to exposed surface phospholipids; increased intracellular metabolic activity; 
and change of surface adhesion receptors to a higher affinity state (Bye et al., 2016; Goggs and Poole, 
2012). 
Firstly, the structural change to the platelets causes a change in platelet shape in such a way that 
increases their surface area, both improving stability of the clot, and providing a larger area of cell 
membrane for the procoagulant molecules involved in secondary haemostasis to work on. This shape 
change is mediated by the platelet cytoskeleton, which is made up of the contractile proteins actin 
and myosin (Bye et al., 2016; Goggs and Poole, 2012).  
Degranulation is the second essential aspect of platelet activation. There are two types of granules 
contained within platelets; Alpha granules and Dense granules. The Alpha granules contain a mixture 
of adhesive proteins, soluble prothrombotic factors, and growth factors. The Dense granules contain 
further soluble prothrombotic factors and platelet agonists. Of the adhesive proteins contained within 
the Alpha granules, some such as fibrinogen are secreted into the plasma, others such as the GPIIb-
IIIa receptor are trafficked to the platelet surface to be expressed, while some such as the glycoprotein 
P-selectin are both expressed and secreted (Rendu and Brohard-Bohn, 2001). P-selectin is a cell-
adhesion molecule, with an important role in inter-platelet aggregation, helping to stabilise the initial 
binding between fibrinogen and platelet GPIIb-IIIa receptors, and so promoting formation of large 
platelet aggregates (Geng et al., 2012). P-selectin is also important in mediating interactions between 
platelets and white blood cells, so forming a key link between haemostasis and inflammation 
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(Crockett-Torabi, 1998). The key soluble factors released pre-formed from the two types of granule 
include ADP, epinephrine, serotonin, histamine, calcium and certain clotting factors including V and 
XI. Of these, ADP is a particularly potent platelet agonist, and causes recruitment and activation of 
further circulating platelets. ADP acts through the P2Y family of receptors, which are G-protein 
coupled receptors constitutively expressed on the platelet surface. Of the family, the P2Y12 receptor 
plays a crucial role in amplifying platelet activation, as binding of ADP leads to further aggregation and 
granule release (Bye et al., 2016; Goggs and Poole, 2012; Murugappan et al., 2004; Rendu and 
Brohard-Bohn, 2001). Additional prothrombotic mediators are also created de-novo and released via 
increased activity of metabolic pathways within the platelets. The most important of these mediators 
is thromboxane, which is created from surface phospholipids via the phospholipase A2 pathway (Figure 
1).  This pathway culminates with excretion of thromboxane A2 (TXA2) into plasma (Hamberg et al., 
1975). There are a number of thromboxane receptors (TXR) making up the thromboxane receptor 
family, but broadly speaking activation of TXR leads to further platelet activation, structural change, 
and cytoplasmic granule release (Goggs and Poole, 2012; Murugappan et al., 2004).  
Several key changes to the phospholipid platelet surface membrane also occur during platelet 
activation. One of these is membrane ‘flipping’, in which phosphatidylserine (PS), a negatively charged 
phospholipid usually expressed on the inner surface of the cell membrane, is flipped to the outer 
surface of the platelet (Goggs and Poole, 2012; Smith, 2009; Yamaji-Hasegawa and Tsujimoto, 2006). 
This has a number of actions, one of which is to make the overall platelet surface more negatively 
charged, which enhances binding of various coagulant molecules, including some of the clotting factor 
complexes involved in secondary haemostasis (Hoffman and Monroe, 2001; Smith, 2009). Some PS 
has also been shown to be shed from the cell membrane into the plasma in certain situations 
(Freikman et al., 2011). An additional membrane action that occurs following platelet activation is 
microvesiculation. This process causes blebbing of the platelet surface membrane, and release of 
small cell fragments known as microparticles. These microparticles express the same populations of 
receptors on their cell surface as the parent platelet and enhance haemostasis by acting as an 
additional surface on which the coagulation complexes can localise (Herring et al., 2013; Hoffman and 
Monroe, 2001; Melki et al., 2017; Smith, 2009). Both PS and microparticles are key to the cell-based 
model of haemostasis, as explored further below. 
Finally, and most crucially for aggregation, platelet activation also causes a structural change in the 
surface integrin GPIIb-IIIa receptor. This conformational change can both be brought about by direct 
binding of vWF to the outer membrane surface of GPIIb-IIIa, or by increased intracellular calcium 
resulting from intracellular signalling downstream of other activated surface receptors acting on the 
intracellular domain of GPIIb-IIIa. This process of activation of GPIIb-IIIa by intracellular signalling 
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initiated by other receptors has been termed ‘inside out’ signalling and is key to understanding how 
triggers other than endothelial injury may lead to platelet aggregation and clot formation. Once 
activated, GPIIb-IIIa is able to bind to fibrinogen in addition to vWF. This step is crucial in enabling the 
platelets to bind not just to the damaged endothelium, but also to other activated platelets to form a 
stable clot (Goggs and Poole, 2012). 
 
Figure 1: Phospholipase A2 Pathway 
 
Abbreviations: COX-1, Cyclooxygenase 1, COX-2, Cyclooxygenase 2, PGI2, prostaglandin I2; PGE2, 
prostaglandin E2, PGD2, Prostaglandin D2, u-11dTXB, urinary 11-dehydrothromboxane B2. 
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1.1.1.3 Platelet aggregation 
Platelet aggregation occurs mainly through fibrinogen binding to the activated GPIIb-IIIa receptors on 
adjacent platelets, and acting as a bridge between activated platelets. As soluble fibrinogen circulates 
free in the plasma, platelet aggregation can occur readily once GPIIb-IIIa has been changed to its active 
form. Platelet aggregation results in a large loose clot of activated platelets held together by fibrinogen 
and to the damaged endothelial surface by vWF and direct integrin binding to collagen. These 
interactions are all relatively weak, however, and so while the primary platelet plug can rapidly limit 
haemorrhage, it is very easily disrupted until further stabilisation of the clot occurs via secondary 
haemostasis (Goggs and Poole, 2012; Weiss et al., 2010). 
1.1.2 Secondary Haemostasis 
Secondary haemostasis is the process by which the primary platelet plug is stabilised by fibrin, formed 
by the plasma-borne coagulation factors. These coagulation factors are a range of serine proteases 
and glycoproteins, the majority of which are synthesised in the liver. They are represented by Roman 
numerals in their inactive form, with an ‘a’ appended to indicate the active form. Classically, secondary 
haemostasis has been thought of as a cascade of enzymatic reactions, divided initially into two parts; 
the extrinsic and intrinsic cascades, which then both culminate in the common cascade. The extrinsic 
pathway is initiated by TF expressed by subendothelial cells, which binds to factor VII in the presence 
of calcium (Ca) and PS acting as cofactors. The activated factor VIIa-Ca-PS-TF complex is then able to 
activate factor X, starting the common pathway. The intrinsic pathway is initiated by surface contact 
of factor XII with exposed collagen. Factor XII then enzymatically activates factor XI, which in turn 
activates factor IX. The activated factor IXa, factor VIIIa, PS and Ca then form a complex which is able 
to activate factor X, again starting the common pathway. Once activated by either route, factor Xa 
then forms a complex known as the prothrombinase complex, which includes factor Xa, factor Va 
released from platelets, PS and Ca. The prothrombinase cleaves prothrombin to thrombin (also known 
as factor IIa), which in turn cleaves fibrinogen to give fibrin monomers. Thrombin is also responsible 
for activating factor XIII, which crosslinks the fibrin into polymers once it has been formed. Crosslinking 
of fibrin is essential to stabilise or mature blood clots (Weiss et al., 2010). Usually, in vivo, the extrinsic 
pathway is the predominant initiator of secondary haemostasis, with the intrinsic and common 
pathways amplifying the thrombin generation. It is important to note that thrombin can also activate 
factor XI of the intrinsic pathway directly, allowing it to amplify its own production significantly. The 
platelet surface, specifically the PS expressed on the surface of activated platelets, is also essential to 
this propagation of thrombin production. Binding to PS both enhances the formation and activity of 
the coagulation factor complexes, and helps to protect them from inhibition by natural anti-coagulant 
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molecules such as protein C and protein S (Hoffman and Monroe, 2001; Smith, 2009). These 
anticoagulant molecules are essential, however, in preventing inappropriate or excessive activation 
of coagulation under normal physiological conditions. Protein C and antithrombin (AT) are serine 
proteases that breakdown a number of the coagulation factors involved in the intrinsic and common 
pathways, while tissue factor pathway inhibitor (TFPI) performs a similar role in inhibiting the extrinsic 
pathway. Activation of these anticoagulant molecules is in turn linked to coagulation in a negative 
feedback loop; for example Protein C is activated by thrombin, using thrombomodulin as a cofactor 
(Kubier and O’Brien, 2012). Overall, the end result of secondary haemostasis is that the platelet plug 
formed in primary haemostasis is strengthened by deposition and crosslinking of fibrin amongst the 
platelets, to form a blood clot.  
1.1.3 Tertiary Haemostasis 
Tertiary haemostasis, also known as fibrinolysis, is the physiologic breakdown of the clot formed by 
the processes of primary and secondary haemostasis. Just as formation of the platelet plug and its 
stabilisation by fibrin are essential to stopping haemorrhage, fibrinolysis is equally essential to allow 
tissue healing and restoration of normal blood flow within the affected vessel. The key player in 
fibrinolysis is plasmin, another serine protease enzyme. Plasmin is produced by the liver as an inactive 
zymogen called plasminogen, which is released into the systemic circulation. Plasminogen then binds 
to fibrin at the site of clotting and is activated to plasmin by tissue plasminogen activator released 
locally by injured endothelial cells. Plasmin can then cleave both soluble fibrinogen, soluble fibrin, and 
crosslinked fibrin. Breakdown of the soluble fibrin and fibrinogen generates substances known as 
fibrin- or fibrinogen-degradation products (FDPs), while breakdown of cross-lined fibrin generates 
substances known as D-dimers. Detection of these various breakdown products has been investigated 
clinically for utility in diagnosing thrombotic disease (Birkbeck et al., 2019; Weiss et al., 2010).  
1.1.4 The cell-based model of coagulation 
While this three-stage classical model of haemostasis very effectively explains the basic processes of 
platelet aggregation, and stabilisation by fibrin, it is in a number of ways an oversimplification, 
particularly when it comes to the cascade model of secondary haemostasis. Clinically the cascade 
model is extremely useful, as the basic tests of secondary haemostasis available to practitioners can 
be divided into whether they reflect the intrinsic or extrinsic pathways. Physiologically, however, there 
are key interactions with other aspects of haemostasis that the cascade model misses out. The cell-
based model of coagulation expands on this initial framework, incorporating not only more of the 
feedback loops between the three stages of haemostasis, but also interactions with the local 
microenvironment in which coagulation occurs, and so better reflecting true in vivo haemostasis. In 
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particular, recent research has further clarified the relationship between coagulation and the cellular 
surface on which it occurs, be that the endothelium or the platelet surface itself (Hoffman and 
Monroe, 2001; Smith, 2009). 
These surface interactions can be both prothrombotic and antithrombotic. A key prothrombotic 
interaction is the need for cofactors for the majority of the clotting factors. These cofactors are 
commonly platelet surface molecules such as PS and TF, but also include calcium which is present in 
far higher concentrations in the local environment around activated platelets than it is in the general 
circulation. The majority of the clotting factors can perform their enzymatic reactions without their 
cofactors, but do so much more quickly when the cofactors are present. Some coagulation factor 
complexes, in particular the prothrombinase complex, can also only form effectively when bound to 
cell surface receptors. Being attached to a surface also offers the clotting factors a localised 
microenvironment that protects them from degradation by the blood-borne anticoagulants protein C, 
protein S, and AT (Hoffman and Monroe, 2001; Smith, 2009). 
The cell-based model also helps to better incorporate the myriad of links between inflammation and 
haemostasis that have been discovered in recent years and are important when considering 
thrombosis in clinical disease states. Several studies have found evidence of increased TF expression 
on intravascular cells, including monocytes, which acts as a potent initiator of coagulation (Mackman, 
2004; Piek et al., 2011). Particularly relevant are microparticles, small membrane derived vesicles free 
within the circulation. As outlined above, microparticles can be derived from activated platelets, but 
can also originate from activated endothelial cells, erythrocytes, and leucocytes in various 
inflammatory diseases. They can act as inappropriate initiators and accelerators of clotting by 
expressing certain surface markers such as PS and TF on their surface, even when vessel wall damage 
and associated haemorrhage are not present (Davizon and López, 2009; Herring et al., 2013). 
As such it has become widely accepted that while the above 3 step division into primary, secondary 
and tertiary haemostasis is useful as an overview and for clinical diagnostics, it is very much a 
simplification. Physiologically these processes are occurring simultaneously and in a complex balance, 
with significant interactions with the vascular endothelium that are not reflected in the classical 
model. The novel concepts involved in the cell based model of coagulation have particularly influenced 
moves to develop new ‘global’ tests of haemostasis that encompass these cellular interactions, in 




1.2 Thromboembolic diseases 
While clot formation can occur as a normal, essential physiological process at the site of vessel injury, 
it can also occur as a pathological process if it occurs in either an inappropriate place or in the absence 
of haemorrhage as an initiating factor. Pathological clot formation is termed thrombosis, with 
individual animals with an active tendency to form pathological clots described as being in a 
prothrombotic state. At the population level, certain diseases are recognised to carry an increased risk 
of thrombosis and may be referred to as ‘prothrombotic diseases’. Pathophysiologically, in its most 
basic sense, thrombosis can be thought of as due to heightened primary or secondary haemostatic 
activity, or reduced fibrinolysis. Within these areas, however, there are multiple different 
abnormalities that may push the balance of prothrombotic and antithrombotic activity in the direction 
of thrombus formation.  
1.2.1 Thromboembolic disease 
Thrombosis is the pathological formation of a clot within a blood vessel, with thromboembolism 
referring to the process by which a clot dislodges from its initial site of formation, travels downstream 
in the circulation, before becoming lodged in a second location. This then causes a degree of 
obstruction to blood flow, and results in hypoxic injury to downstream tissues termed ischemia. It is 
important to note that thrombosis can occur in either the arterial or the venous sides of the 
circulation, with subtly different clot compositions, triggers for clot formation, and downstream 
sequelae (Weiss et al., 2010).  
Thromboembolism is a major cause of morbidity and mortality in both humans and animals. In the 
human field, thrombosis of coronary arteries causing myocardial infarction is one of the leading causes 
of death in the developed world. Diseases such as deep vein thrombosis of the distal limbs, cerebral 
thrombosis causing strokes, and PTE causing respiratory distress are also significant causes of 
morbidity and mortality. In the US alone, 400,000 patients per year are affected by non-fatal PTE, 
while another 200,000 die from this disease (Long and Koyfman, 2017). In the veterinary field, distal 
aortic thromboembolism of the hindlimbs in cats is a common complication of cardiomyopathy, and 
one of the major causes of mortality in this condition. Although seen less commonly, aortic thrombosis 
in dogs can occur secondary to a number of different common conditions, including cardiac disease, 
neoplasia, hypothyroidism, hyperadrenocorticism, protein losing enteropathy, protein losing 
nephropathy, and diabetes mellitus (Williams et al., 2017). Thromboembolic disease including PTE is 
also a major cause of mortality in dogs with immune mediated haemolytic anaemia (IMHA) 
(deLaforcade et al., 2019; Kidd and Mackman, 2013; Swann et al., 2019). Clinically, some animals 
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present for veterinary care due to signs related to thromboembolic disease itself, rather than due to 
signs of the underlying disease process. This includes neurological signs due to cerebral or cerebellar 
emboli, tachypnoea or dyspnoea with PTE, and hindlimb dysfunction caused by aortic thrombi. 
Despite improvements in our understanding of the pathophysiology of thrombosis, however, in some 
studies up to half of dogs presenting with documentable thrombi have no detectable underlying 
predisposing condition (Winter et al., 2012). It is also important to note that not all thrombi are 
associated with clinical signs. In the human field, the prevalence of incidental emboli on thoracic and 
abdominal CT scans varies from 0.5-5%, while post mortem studies have identified incidental thrombi 
in between 9% and 63% of patients (Long and Koyfman, 2017). While no specific studies have been 
performed investigating the prevalence of incidental thrombi in veterinary patients, it is likely the 
prevalence is similar.  
1.2.1.1 Pathophysiology of thrombosis 
Broadly speaking, the pathophysiology of thrombosis is the same as physiological clot formation, but 
with an inappropriate trigger. In the 1800s the famous German physician Rudolf Virchow produced a 
body of work investigating the pathophysiology of thrombosis. He identified that predisposing factors 
could be grouped into three key areas, which have since become known as Virchow’s triad (Bagot and 
Arya, 2008). These three areas are stasis of blood flow, endothelial injury, and hypercoagulability of 
the blood itself. While modern understanding of thrombosis has progressed, especially with regards 
to the underlying molecular mechanisms behind hypercoagulability, this key framework of thrombosis 
pathophysiology has endured.  
In veterinary medicine, most research has focused on the abnormalities within the blood itself that 
may lead to hypercoagulability, and subsequently to thrombosis. These abnormalities encompass 
both increases in prothrombotic elements, and reduced antithrombotic elements. Some examples of 
the former include increased TF production, increased procoagulant microparticle levels, increased 
concentrations of soluble prothrombotic factors such as thromboxane and ADP, and increased 
activation of platelets (Jeffery et al., 2016; Kidd and Mackman, 2013; Piek et al., 2011; Shropshire et 
al., 2018). Reductions in anti-thrombotic mechanisms can include decreased levels of AT, 
thrombomodulin, protein C and TFPI. 
The second corner of Virchow’s triad, endothelial function, similarly normally exists in a balance of 
prothrombotic and antithrombotic activity. Increases in the prothrombotic activity, best exemplified 
by increased TF expression following injury, or decreased normal antithrombotic activity can promote 
thrombus formation. The normal antithrombotic activities of the endothelium include secretion of 
prostacyclin and nitric oxide (NO), both of which act directly on platelets to inhibit activation (Cheng 
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et al., 2002). Endothelial dysfunction alters this normal balance by reducing prostacyclin and NO 
excretion, and by increasing expression of prothrombotic surface molecules. Endothelial dysfunction 
can occur in various situations, most prominently in atherosclerotic plaque formation in people, but 
also in inflammatory diseases such as sepsis where vasculitis can occur (Poredoš, 2001).  
The final aspect to Virchow’s triad, stasis of blood flow, is harder to test for and quantify clinically, but 
equally important to thrombosis in certain situations. Specifically, blood stasis is extremely important 
in the pathogenesis of human deep vein thrombosis (DVT), which is commonly seen in patients 
immobilised in hospital for prolonged periods of time (Bates, 2012). In the veterinary field, blood stasis 
in the enlarged left atrium and auricle is thought to be a key mechanism behind thrombus formation 
in cats with cardiac dysfunction (deLaforcade et al., 2019). 
Overall while abnormalities in all these three areas can inappropriately activate haemostasis and 
contribute to thrombus formation, differing mechanisms seem to predominately drive thrombosis in 
different underlying diseases. There are several diseases that we see a high incidence of thrombosis 
in in canine patients, the three of main relevance to this thesis being IMHA, PLN and PLE. Prior to 
looking at what is known of the specific pathophysiology of thrombosis in those three conditions, it is 
first relevant to outline how we detect thrombi in individual patients. Being able to reliably detect 
when thrombi are, and equally importantly are not, present in a patient is crucial to subsequently 
evaluating which predisposing abnormalities of Virchow’s triad are present in patients with the same 
condition who do develop thrombi, compared to those who don’t. Unfortunately, as outlined below, 
while the diagnosis of thrombosis and thromboembolism can be very straightforward, it can also be 
extremely difficult. 
1.2.2 Detecting thrombosis 
Clinically, thrombosis is often suspected in veterinary patients on the basis of clinical signs, which in 
turn vary depending on the site of thrombosis. The most commonly seen clinical signs of potential 
thrombi include sudden unexplained onset of respiratory distress, sudden onset neurological disease, 
or sudden onset of localised oedema. However these are all very non-specific. For example, in the 
case of PTE, the associated respiratory difficulty is often only attributed to PTE when other more easily 
detected cardiac and respiratory causes are excluded, and may only be suspected in dogs with 
conditions known or believed to predispose to thromboembolic complications. Equally, while most 
dogs with aortic thromboembolism (ATE) will present with hindlimb weakness, this can vary from 
being very mild exercise intolerance to hindlimb paresis or even complete paraplegia, with the severity 
of the clinical signs likely a reflection of the speed of onset of the clot. In studies of dogs diagnosed 
with ATEs, 15-47% present with acute signs, while 43-69% present with more chronic insidious onset 
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signs (Williams et al., 2017). Usually a combination of diagnostic imaging and laboratory tests are used 
to confirm a clinical suspicion of thrombosis, however the methods available have very variable 
sensitivities and specificities, as explored further below. 
1.2.2.1 Imaging for detecting thrombosis 
At present, diagnostic imaging is the only definitive way of confirming thrombosis in patients. The site 
of thrombosis does, however, have a significant impact on how effective imaging is in this role. The 
main groups of areas in which imaging may be used to detect thrombi are the large blood vessels in 
the abdomen and extremities, the pulmonary vasculature, the small vasculature within the central 
nervous system and finally the small capillaries in end-organs throughout the body. 
In veterinary patients, when thrombi occur in the larger blood vessels such as the renal veins, splenic 
vein, femoral arteries or vena cava, they are often most easily visualised by means of ultrasonography. 
The use of Doppler flow can improve thrombus identification, since it allows evaluation of blood flow 
around the thrombus. In the human field, where deep vein thrombosis of the lower limbs are the 
commonest large-vessel thrombi, ultrasonography is also the first line test for detection and 
monitoring due to its easy accessibility (Karande et al., 2016). Contrast CT venography is, however, 
considered the gold standard with a sensitivity of between 71-100% and a specificity of 93-100% in 
meta-analyses. It is used particularly when the clinical index of suspicion is high, but ultrasound is 
negative. It is however much more expensive and invasive for the patient. Similarly, when assessing 
for portal vein thrombi in people, abdominal ultrasound is often used first, with a sensitivity of 
between 80-100%. CT and MRI can, however, provide additional information and help identify thrombi 
associated with malignancy (Keeling and Alikhan, 2013). Similarly, the use of MRI to detect aortic 
thrombi in dogs has also been reported however this is rarely used clinically due to the increased cost, 
time, and requirement for general anaesthesia compared to ultrasonography (Sharpley et al., 2009). 
Pulmonary thrombi represent a particular diagnostic imaging challenge in both veterinary and human 
patients. In human medicine ventilation-perfusion scanning using nuclear scintigraphy was historically 
the gold standard for PTE detection. In recent years, however, the increasing availability and ease of 
use of CT scanners has made CT pulmonary angiography the current test of choice. Newer 
multidetector scanners have also enabled detection of thrombi in the subsegmental pulmonary 
vessels as small as 2 to 3mm diameter (Raja et al., 2015). CT pulmonary angiography has also recently 
been investigated for utility in identifying PTE in dogs. In a study of 12 dogs with IMHA suspected to 
have PTE based on unexplained respiratory distress, CTPA confirmed the diagnosis in four (33%) and 
was strongly suspicious for PTE in a further three (24%). The authors noted that while the sensitivity 
of CTPA in humans for PTE is high, between 83 and 100%, differences in CT slice thickness and patient 
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size mean that the sensitivity for dogs, particularly small dogs, is likely to be much lower. Given the 
lack of a gold standard for diagnosis of PTE, the actual diagnostic utility of CTPA could not be assessed, 
but was accurate in three dogs that underwent post-mortem examination. As such CTPA is a promising 
option for canine PTE detection in future, particularly as newer CT technology becomes available in 
the veterinary field.  
By far the biggest challenge for detecting thrombi, however, is when they occur in the smallest venules, 
arterioles and capillaries in the end organs. In these locations the thrombi are not visible to 
ultrasonography, and so commonly only the end-organ effects of the thrombus are seen, such as focal 
splenic or renal infarctions. Similarly in the CNS, areas of cerebral or cerebellar ischaemia due to 
thrombi may be visualised on MRI, but the causative thrombi themselves are not usually visualised 
unless venous angiography is used (Weimar et al., 2012).  
Overall while a positive finding of a thrombus on imaging is likely to be reliable, negative results are 
likely to be less so, due to low sensitivity for small clots. As such a number of laboratory tests have 
been developed to aid in the detection of thrombi. These tests are ideally used to increase or decrease 
the index of suspicion for a thrombus, so clinicians can decide whether further advanced imaging is 
likely to be useful.  
1.2.2.2 The role of laboratory tests in detecting thrombosis 
A number of the laboratory tests of clotting have been evaluated for their utility in helping to detect 
thrombosis. The classical tests of haemostasis; fibrinogen concentration, platelet count, Prothrombin 
time (PT) and activated partial thromboplastin tine (aPTT) have been found to have variable 
associations with the presence of thrombi and are all very non-specific. As such they are widely 
accepted to be unhelpful in screening for thrombosis, although they may have a role in detecting a 
prothrombotic or hypercoagulable state. As markers of clot breakdown, tests of FDPs and D-dimers 
were developed with the aim of being more sensitive for thrombosis, but clinically have been found 
to be poorly specific, and in many cases also poorly sensitive. Investigators have also started to explore 
whether the newer viscoelastic tests such as  Thromboelastography (TEG) have any utility in 
thrombosis detection, with varying conclusions. Specific detail about TEG methodology and 
interpretation can be found in section 1.3.1.2 and in Figure 2.  
D-dimers have been widely suggested to be a useful rule-out test for thrombi, on the basis that if a 
clot is present, some degree of fibrinolysis would be expected to be occurring. However clinically, the 
utility seems to vary depending on the location of the thrombosis. For screening for PTE in people, D-
dimers have been found to have a negative predictive value of 99%, albeit with a poor specificity of 
around 41% (Perrier et al., 1997). As such, for PTE there are well recognised clinical algorithms in which 
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a positive D-dimer result in an at-risk patient acts as a trigger for further diagnostic imaging (Raja et 
al., 2015). However the same does not necessarily hold true for other clot types. A meta-analysis 
evaluating D-dimers for screening for human DVT found a similarly low specificity, but also found a 
lower than expected sensitivity, ranging from 51-100%, with a third of the studies reporting a 
sensitivity <90%. Overall the authors concluded that the use of negative D-dimers as a rule-out for 
DVT could not be recommended (Heim et al., 2004).  In both situations, the low specificity means that 
positive D-dimer results may indicate the presence of a thrombus, but cannot be used as a diagnostic 
test alone. Fewer studies have been performed in the veterinary field, but on the whole they show 
similar results. Based on detection of clots at post-mortem, D-dimers have been shown to have a poor 
specificity of ~30%, but also a low sensitivity of 80-87% at clinically relevant cut-offs (Epstein et al., 
2013). Authors of one study concluded that D-dimers could be used to exclude thrombi only at a level 
of 0 ng/ml (Nelson and Andreasen, 2003). Unlike in the human field, however, initial studies have 
failed to find an association between D-dimer levels and the presence or absence of PTE on CT 
angiograms (Goggs et al., 2014) Overall while D-dimers may have some utility in guiding the index of 
suspicion for thrombosis in people, the situation in dogs remains unclear.  
The newer viscoelastic tests such as TEG have mainly been used to evaluate for hyper- and hypo-
coagulability. A few studies have, however, looked for associations with the presence of thrombosis, 
but at present there appears to be no association between TEG variables and either thrombosis 
detected either post mortem, or PTE detected via CT angiography. In the first study looking for an 
association between TEG and subsequent post-mortem evidence of thrombosis, the authors found no 
statistically significant association between TEG variables and necropsy evidence of thrombosis. Of 
note however, at post mortem 75% of the thrombi found were deemed to be acute, 10% subacute, 
and 15% chronic, and the time between TEG and necropsy ranged from 1-7 days, so it is likely that 
there was significant variability between the time the TEG was performed and the time of clot 
formation in individual dogs, which may have impacted on the findings (Thawley et al., 2016).  In 
another study comparing TEG findings in 6 dogs with PTE and 19 sick dogs without PTE, as determined 
by CT angiography, no consistent differences in TEG traces alone were found between the groups. 
Additionally, while some of the dogs with PTE had hypercoagulable TEG traces as was anticipated, 
some had normocoagulable and hypocoagulable traces (Marschner et al., 2017). It is important to 
note when evaluating TEG traces between studies, that there are a number of sources of variability in 
the methodology. Most notably, different activators, including collagen and kaolin can be used to start 
the in vitro clotting process, while some early TEG studies used no activators at all. While there are 
now consensus guidelines on how TEG should be run, there is still known to be significant inter-
operator variability in results generated via the same machine, let alone between devices at different 
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centres (Goggs et al., 2014). As such at present, the utility of TEG for helping to guide the index of 
suspicion for the presence of thrombosis is unclear, but seems to be low. 
1.2.2.3 Post mortem thrombosis detection 
It is important to note when evaluating the utility of these different tests for detecting thrombosis, 
that there is currently no reliable gold standard against which to compare. Although many studies use 
post-mortem as the gold standard for evidence of thrombosis, or absence thereof, there are some 
noteworthy limitations to this approach. Even in dogs undergoing a full post-mortem examination 
thrombosis can be difficult to determine definitively, both due to dissolution of ante-mortem clots, 
and due to formation of post-mortem clots. Post-mortem fibrinolysis has been shown to start 
occurring as quickly as 3 hours after death in dogs. Additionally, smaller clots in minor vasculature may 
not always be found. For example, in one study of 29 dogs with PM confirmed pulmonary thrombi, 
4/19 dogs had only very small thrombi present, which required extensive dissection to detect, and 
could have been easily missed (Moser et al., 1973). 
In conclusion, a diagnosis of a thromboembolic event in veterinary patients is most commonly a 
suspected rather than confirmed diagnosis, based on a combination of clinical signs, presence of 
underlying risk factors, and imaging findings. In humans, unlike in dogs, there are some defined 
guidelines for when to screen patients for thrombosis, using combinations of laboratory testing and 
diagnostic imaging, however the starting point is always a set of suspicious clinical signs, as blanket 
screening is likely to produce large numbers of false positive results. As yet, while similar schemes 
have been suggested for PTE in dogs, they are not yet validated, and overall testing for thrombosis is 
very much down to individual clinician judgement. 
1.2.3 Diseases with an increased prevalence of thrombosis  
As mentioned previously, there is an increased prevalence of thrombosis in dogs with certain diseases. 
For the purposes of this thesis these diseases will be referred to as ‘prothrombotic diseases’, although 
it is important to note that an individual animal with a ‘prothrombotic disease’ may not have an 
actively increased risk of thrombosis at all timepoints of its disease course. Equally not all individuals 
with the same prothrombotic disease may be at equal risk of thrombosis, due to the numerous 
different pathophysiological mechanisms that influence haemostasis, which will each be abnormal to 
varying degrees in individual animals. Conditions considered to be prothrombotic in veterinary 
medicine include IMHA, PLN, acute necrotising pancreatitis, hyperadrenocorticism, certain neoplasias, 
some cases of sepsis, PLE, and cardiac disease in cats but not in dogs (deLaforcade et al., 2019).  Of 
these conditions, three have been selected as the focus of this thesis, for various reasons. IMHA has 
by far the highest prevalence of thrombotic complications and is a very common cause of referral of 
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animals to referral hospitals for care. There is also an extensive pre-existing body of work suggesting 
that platelet activation is important in the pathogenesis of thrombosis in IMHA. Equally both PLN and 
PLE, while associated with a lower prevalence of thrombosis, are common diagnoses for patients seen 
through the internal medicine service. In contrast to IMHA, however, little work has been done 
investigating platelet activation in thrombosis in these patients, but newer studies from similar 
diseases in the human field raise the question of whether the role of platelets has historically been 
underappreciated.  
1.2.3.1 IMHA 
The first of the three diseases of relevance to this thesis, IMHA is a commonly seen disease in dogs, in 
which immune-mediated destruction of red blood cells occurs. The mechanism behind this is a 
classical type II hypersensitivity response which involves autoantibody production and antibody-
mediated cytotoxicity. This can lead to either haemolysis of red cells within the vasculature, due to 
activation of complement and formation of the membrane attack complex, or extravascular 
haemolysis when the autoantibodies bind to the red cells and act as opsonins, leading to phagocytosis 
by macrophages located primarily in the liver and spleen. IMHA can be classed as a primary disease 
due to immune dysregulation of unknown aetiology, or secondary due to a wide range of triggers such 
as infection, neoplasia, vaccination, and various drugs and toxins. Despite advances in our 
understanding of the pathophysiology of IMHA in recent years, the mortality rate in this disease 
remains high, reported as between 30 and 70% (Goggs et al., 2015).  
There are a number of studies evaluating risk factors for mortality in canine IMHA, and a few also 
investigating specific risk factors for thrombosis. Individual prognostic factors identified for IMHA 
include thrombocytopenia, hyperbilirubinemia, neutrophilia, PT and aPTT, hypoalbuminemia, 
hyperkalaemia, bicarbonate concentration, increased creatinine kinase (CK) and alanine 
aminotransferase (ALT) activity, severity of azotaemia, presence of pigmenturia, and positive 
autoagglutination (Carr et al., 2002; Goggs et al., 2015; Piek et al., 2008; Swann and Skelly, 2015).  A 
number of scoring systems for disease severity have also been evaluated for prognostic utility in IMHA. 
Of these, the American Association of Anaesthesiologists (ASA) score is a non-specific scoring system 
initially developed to stratify risk for patients undergoing general anaesthesia. ASA scores are assigned 
as follows:  Grade 1, Normal; Grade 2, Mild systemic disease; Grade 3, Severe systemic disease; Grade 
4, Life‐threatening systemic disease; Grade 5, Moribund patient, not expected to survive. In the largest 
study of IMHA patients to date, ASA score >3 had an increased odds ratio of 2.7 (95% CI 1.1-6.9) for 
mortality (Goggs et al., 2015). Two disease specific scores have also been developed for IMHA; the 
Tokyo score and the canine haemolytic anaemia objective score (CHAOS). Of these CHAOS score >3 
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has been found to be associated with an increased odds ratio of 4.2 times (95% CI 2.2-8.0) risk of 
mortality during hospitalisation (Goggs et al., 2015). CHAOS score is calculated based on patient age, 
rectal temperature, presence or absence of autoagglutination, and serum albumin and bilirubin levels 
as shown in Table 2. 
Table 2: Canine haemolytic anaemia objective score (CHAOS) 
Age (year) If ≥7 score 2, otherwise score 0 
Temperature (°F) If ≥102.0 score 1, otherwise score 0 
Agglutination If present score 1, otherwise score 0 
Albumin (g/dl) If <3.0 score 1, otherwise score 0 
Bilirubin (mg/dl) If ≥5.0 score 2, otherwise score 0 
Total Maximum score 7 
 
 
1.2.3.1.1 Prevalence of thrombosis in IMHA 
One of the main causes of morbidity and mortality in these patients is thromboembolism, with the 
prevalence of thrombosis being as high as 80% at necropsy (McManus and Craig, 2001). As such, IMHA 
is considered a disease with a high risk of thromboembolic complications, particularly in the first 2 
weeks of therapy (deLaforcade et al., 2019). Most common are venous thrombi, with portal vein, 
cephalic vein, splenic vein and hepatic vein thrombosis all being reported. Venous thrombi that 
dislodge from their initial site of formation and embolise via the vasculature to a distant site are also 
an important cause of pulmonary arterial thromboembolism. Arterial thrombi can also be seen, 
however, with splenic, renal, cardiac, iliac and mesenteric artery infarction being described in the 
literature (McManus and Craig, 2001; Piek et al., 2008). Unlike risk factors for mortality, individual 
patient risk factors for thrombosis have not been as widely investigated in IMHA. Risk factors for 
thrombosis identified so far include severe thrombocytopenia <50, severe hyperbilirubinemia  
(>85.5umol/l), hypoalbuminemia (<26g/l), increased ALP (>60IU/l ), moderate to severe leucocytosis 
(>28x109/l ), and D-dimers over 1000ng/ml (Carr et al., 2002; McManus and Craig, 2001; Nelson and 
Andreasen, 2003) 
In human medicine, autoimmune haemolytic anaemia (AIHA) is a very rare disease compared to in 
dogs, occurring at a rate of only 1-3 cases per 100,000 person-years. Just as in veterinary medicine, 
however, there is an increased risk of thrombosis, with thrombi occurring in approximately 1 in 5 
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patients with AIHA. In a recent meta-analysis, the risk in AIHA patients was around 2.6 times that of 
controls (Ungprasert et al., 2015).  
1.2.3.1.2 Pathophysiology of thrombosis in IMHA 
Of the three diseases covered in this thesis, by far the largest amount of research has been done into 
the underlying cause of thrombosis in IMHA. Overall, the mechanism behind the prothrombotic 
tendency in IMHA is most likely multifactorial. Of the three aspects of Virchows triad, abnormalities 
to the vasculature and haemostasis itself seem to be the main contributors, with significant 
interactions with inflammation. IMHA is well recognised as being a highly inflammatory state, and 
there are numerous proposed routes that this leads to both endothelial injury and activation of 
haemostasis (Kidd and Mackman, 2013). Prothrombotic mechanisms suggested to date in IMHA 
include increased platelet reactivity, exposure of TF intravascularly, exposure of PS on damaged 
erythrocytes and microparticles, release of procoagulant thromboplastin and heme from lysed RBCs, 
alterations in coagulation factor levels, and more generally the effects of hypoxia, release of 
inflammatory mediators, endothelial injury, and alterations to blood viscosity due to anaemia (Fenty 
et al., 2011; Hamzianpour and Chan, 2016; Kidd et al., 2015; Kidd and Mackman, 2013; Piek et al., 
2011; Ridyard et al., 2010; Scott-Moncrieff et al., 2001; Ungprasert et al., 2015; Weiss and Brazzell, 
2006a). There are varying strengths of evidence base behind these suggestions, which are outlined in 
the following section. 
Primary haemostatic abnormalities 
Starting with primary haemostatic abnormalities, there are a number of studies evaluating the 
contribution of increased platelet activation to the prothrombotic state in canine IMHA. A study by 
Weiss and Brazzell in 2006 found evidence supporting the idea that there is a population of circulating 
activated platelets in dogs with IMHA. In this study they assessed platelet P-selectin surface expression 
using flow cytometry at baseline in 20 normal dogs and 20 dogs with primary IMHA. They found the 
IMHA dogs had an 8.1-fold greater median P-selectin expression than the healthy reference dogs, 
however there was a degree of overlap, with only 15 of the 20 IMHA dogs having higher than reference 
P-selectin levels when the dogs were assessed individually. The percentage of platelets with increased 
P-selectin in these dogs at baseline was also very inconsistent, varying from 12.4 to 43.6%. This study 
suggests that some dogs with IMHA do have platelets circulating in an activated state, but also raises 
the question of whether differences in the proportion of circulating activated platelets may contribute 
to the risk of thrombosis in individual patients (Weiss and Brazzell, 2006b). It has been questioned, 
however, whether the increased P-selectin is specific to the immune-mediated pathology in IMHA, or 
whether it is also seen more generally in inflammatory conditions, not all of which are prothrombotic. 
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A study by Moritz et al 2005 showed a high mean P-selectin in 8/11 dogs with non-septic inflammation, 
and 4/9 with septic inflammation. Likewise there was an increased percentage of platelets with high 
P-selectin levels in 8 of 11 (73%) dogs with non-septic inflammatory disease, and 5 of 9 (56%) dogs 
with septic inflammatory disease. From this the authors concluded that at least 60% of dogs with 
inflammatory disease had circulating activated platelets (Moritz et al., 2005). A similar study in 2015 
using flow cytometry also found evidence of platelet hyper-reactivity in critically ill dogs (Majoy et al., 
2015). This raises the question of whether platelet activation alone in IMHA can be blamed for the 
increased thrombotic risk, given that many other canine inflammatory conditions don’t show the same 
incidence of thrombotic disease that IMHA does. Additionally, some investigators using P-selectin 
have found conflicting results to those above. One such study found no alteration to platelet P-selectin 
expression overall in 14 dogs with IMHA compared to normal controls using whole blood flow 
cytometry. When the subset of 5 dogs with severe thrombocytopenia was compared to the normal 
controls however, there was a significant increase in platelet P-selectin. They also identified a strong 
association between thrombocytopenia and the other markers of platelet activation; platelet 
fibrinogen binding and platelet derived microparticles (Ridyard et al., 2010). Overall these studies 
using P-selectin do provide evidence that some dogs with IMHA will have increased platelet activation 
compared to normal dogs, but also add to the theory that different individuals with IMHA likely show 
different spectrums of abnormalities of haemostasis contributing to their overall risk of thrombosis. 
Additional evidence for a role of platelets in the prothrombotic nature of IMHA comes from studies 
looking at routine platelet indices in clinical cases. In a retrospective case-control study, Zoia et al 
showed a significantly lower plasma mean platelet component (MPC) concentration in dogs with IMHA 
as compared to both healthy controls and to a population of dogs with other systemic illnesses (Zoia 
et al., 2018). MPC is a measure of platelet density, measured using light scatter on some automated 
haematology analysers. Previous work has found that MPC can be used to assess platelet activation, 
since the action of degranulation reduces the platelet density, and so the measured MPC (Chapman 
et al., 2003; Macey et al., 1999). MPC has also been found to correlate with P-selectin expression 
(Moritz et al., 2005). Low MPC in dogs with IMHA and those with DIC compared to healthy dogs and 
dogs with sepsis was also identified in a study primarily assessing intravascular TF expression in IMHA 
patients (Piek et al., 2011). Overall these studies show convincing evidence of increased platelet 
activation in dogs with IMHA. As yet, however, links between increased platelet activation and 
thrombosis itself have not been widely explored.  
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Other haemostatic abnormalities 
Moving onto secondary haemostatic abnormalities, there is also a substantial body of work looking at 
abnormalities of the clotting cascade causing hypercoagulability in dogs with IMHA. Decreased AT, 
prolonged aPTT, prolonged PT and elevated D-dimers are commonly reported in dogs with IMHA, 
consistent with activation of coagulation and consumption of clotting factors (Scott-Moncrieff et al., 
2001). In one study reduced activities of all clotting factors apart from VIII and IX was found in dogs 
with primary IMHA, consistent with the presence of a consumptive coagulopathy in at least some of 
these dogs (Piek et al., 2011). They also identified a correlation between aPTT and survival in 
multivariate analysis. The significance of these alterations as a cause of thrombosis rather than as a 
result of thrombosis however is unclear, and in many studies no consistent alterations to the clotting 
times have been seen. For example, in one such study, only one of 29 dogs with IMHA had a mildly 
prolonged PT, while 18 had mild prolongation of the aPTT (Goggs et al., 2012).  
Several investigators have also looked into global hypercoagulability in IMHA using the newer 
viscoelastic assays TEG and rotational thromboelastometry (ROTEM), and identified a number of 
abnormalities. The first such retrospective study of 39 dogs diagnosed with IMHA found that 33 of 
them (85%) had hypercoagulable TEG traces based on calculation of a coagulation index (CI). This 
coagulation index was calculated from the four routinely assessed TEG variables (R, α, K and MA), and 
the calculation had previously been developed in dogs to give a single overall number as a 
representation of coagulation status. Overall 76% of the TEG values were hypercoagulable (Sinnott 
and Otto, 2009). More recently, using standard TEG parameters, Goggs et al also found that dogs with 
IMHA were significantly hypercoagulable compared to controls (Goggs et al., 2012). Due to concerns 
that many of the dogs in previous studies had already been started on medication at the time of 
sampling, some of which may itself affect coagulation, Fenty et al, assessed 11 dogs with IMHA using 
TEG specifically prior to administration of any immunosuppressants, anticoagulants, or transfusions. 
While no overall CI was calculated, again all 11 dogs in this study were deemed hypercoagulable, with 
a lower median K, and higher median α and median MA (Fenty et al., 2011). Some investigators have 
also attempted to pick apart the impact of platelet and coagulation factors on TEG trace abnormalities. 
In one such study, authors found that the majority (70%) of 27 dogs with IMHA had 
thromboelastograms consistent with hypercoagulability, and further characterised 50% of the 
hypercoagulable dogs as being due to platelet hyperreactivity, and 50% as due to clotting factors 
(Hamzianpour and Chan, 2016). Overall, although  there remains debate over how to standardise 
viscoelastic test methodology so results of these studies are clinically applicable between different 
hospitals, these tests provide evidence of a variety of abnormalities of secondary haemostasis present 
in dogs with IMHA. 
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Links with inflammation 
While as outlined above, there is clearly a growing body of evidence to suggest alterations to platelet 
activation and the clotting cascade are present in IMHA, a range of other abnormalities associated 
with the pro-inflammatory state have been found that may make these patients prothrombotic. The 
first of these is hyperfibrinogenaemia. Numerous studies have identified increased circulating 
fibrinogen levels in dogs with IMHA (Fenty et al., 2011; Kidd et al., 2015; Piek et al., 2011; Scott-
Moncrieff et al., 2001). Fibrinogen is an acute phase protein, produced by the liver in many 
inflammatory conditions, but is also the basis for fibrin production by prothrombin. As such, there has 
been some suggestion that hyperfibrinogenaemia may in part contribute to the hypercoagulable state.  
Equally, increased expression of TF, both on endothelial cells and other cell types, has been proposed 
as a prothrombotic trigger. In a study by Piek et al, whole blood TF gene expression has been found to 
be high in dogs with primary IMHA. It is of note, however, that TF expression showed no significant 
association with death in the survival analysis, and blood TF expression was also high in dogs with 
neoplasia and sepsis when compared with normal healthy controls. The authors additionally found an 
association between the increase in TF expression and the platelet parameters mean platelet volume 
(MPV), mean platelet mass (MPM) and platelet distribution width (PDW), and hypothesised that this 
suggests a role for platelets in the increased TF expression (Piek et al., 2011). Previous studies have 
found TF mRNA expression in platelets, but also in monocytes and neutrophils (Mezzano et al., 2008; 
Nakamura et al., 2004; Østerud, 2010) . In the human field, heme released from haemolysed red blood 
cells has also been found to induce expression of TF on endothelial cells, and is a potential mechanism 
behind the increased TF levels found in the canine IMHA studies (Setty et al., 2008).  
Investigators have also found evidence of increased microparticle numbers in dogs with IMHA (Kidd 
et al., 2015; Ridyard et al., 2010). Microparticles are produced by blebbing of the cell membrane of 
multiple different cell types, including RBC, platelets, endothelial cells, and leucocytes such as 
monocytes. Numerous studies in humans have shown that microparticles from all these cell lines can 
express prothrombotic markers such as PS on their surface. This expression has been hypothesised to 
be how microparticles contribute to a prothrombotic state, as in particular platelet-derived 
microparticles have been shown to be more procoagulant than activated platelets by a factor of 50 to 
100 times (Sinauridze et al., 2007). In support of this, a study by Kidd et al evaluating microparticles  
in dogs with IMHA found that while the absolute number of microparticles positive for PS surface 
expression (PS+) was not significantly higher in dogs with IMHA than control dogs, the median in vitro 
thrombin generation, used as a measure of procoagulant activity, associated with those microparticles 
was higher for the IMHA dogs than for the controls. Notably, however, this median increase in the MP 
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procoagulant activity in the group overall was almost entirely due to three individual IMHA dogs, with 
10 of the 15 dogs having levels comparable to the controls. Notably, those 3 IMHA dogs all showed 
evidence of intravascular haemolysis based on marked hemoglobinemia.  The authors also found 
higher factor Xa generation from microparticles in 4 of the 15 IMHA patients than controls, and 
specifically higher tissue-factor dependent FXa production in some. They did not, however, correlate 
these findings with clinical outcome, so whether thrombosis is more likely when MP procoagulant 
activity is increased is unknown (Kidd et al., 2015). Taken together, however, these findings add weight 
to the theory that microparticles are involved in the prothrombotic state in some, although possibly 
not all, dogs with IMHA. In the human field, it has also been found that microparticle levels increased 
in stored red blood cells used for transfusion (Rubin et al., 2010). Given that a significant proportion 
of dogs with IMHA will require transfusion support, it has been suggested that transfusion therapy 
may also be a contributor to prothrombotic tendencies in our patients. Similarly, damage to red cells 
caused by haemolysis leads to exposure of normally intracellular antigens to the circulation. Of 
particular relevance is the exposure of PS on damaged red cells (Ataga, 2009). In the same study by 
Kidd et al evaluating procoagulant activity associated with microparticles in dogs, mechanical 
haemolysis increased in vitro procoagulant activity associated with PS+ and TF+ microparticles (Kidd 
et al., 2015). While the cause of this was not specifically investigated, either red cell fragments 
expressing PS or red cell derived microparticles could explain these findings. Additionally, substances 
such as heme and ADP released from red cells can act as erythrocyte-derived damage-associated 
molecular pattern molecules (DAMPs), and by binding to pattern recognition receptors on multiple 
cell types including platelets, can promote both inflammation and thrombosis (Vogel and Thein, 2018).  
Finally, increases in blood-borne chromatin complexes released by activated neutrophils, named 
neutrophil extracellular traps (NETs), have also been shown to be present in dogs with IMHA. In a 
prospective study assessing NETs concentrations in 35 dogs with IMHA, there was also a trend towards 
higher NETs levels in non-survivors than survivors, although this did not reach statistical significance 
(Lawson et al., 2018). Several studies in humans and rodent models have implicated NETs in the 
development of thrombi, in part by acting as a trigger for platelet activation, and so increases in NETs 
has been proposed as another contributor to the prothrombotic state in canine IMHA patients (Brill 
et al., 2012).  
Overall, the mechanism behind the prothrombotic tendency in dogs with IMHA is likely multifactorial, 
and may differ in severity between individual patients. While better understanding of the molecular 
mechanisms behind the thrombotic tendency in IMHA may identify targets for therapeutic 
intervention, applying this information clinically will remain difficult without an easily accessible test 




The second disease of interest in this thesis, PLN, is also relatively commonly seen in canine patients. 
Damage to the renal glomeruli from various disease processes causes disruption to the normal 
filtration barrier, resulting in increased protein loss in the urine (Littman, 2011). Lower molecular 
weight proteins such as albumin and AT are most easily lost, although the overall charge on the 
molecules also affects how easily they pass through the glomerular membrane. Affected dogs are 
commonly hypoalbuminaemic, and can have associated clinical signs of weight loss, muscle wasting, 
azotaemia, peripheral oedema and ascites. The occurrence of the combination of hypoalbuminemia, 
marked proteinuria, hyperlipidaemia and fluid accumulation such as ascites or peripheral oedema is 
termed nephrotic syndrome, and is a rare but severe complication of PLN (Klosterman et al., 2011; 
Klosterman and Pressler, 2011; Littman, 2011).  
Similarly to IMHA, PLN can be secondary to a variety of disease processes, such as neoplasia and 
inflammatory diseases, and can be a primary condition in its own right. Primary PLN can also be 
congenital, or an acquired abnormality. In veterinary medicine, a diagnosis of PLN is based on 
detection of significant proteinuria, and establishing it is of renal origin by exclusion of pre- and post- 
renal causes (Littman, 2011). Pre-renal causes of proteinuria involve increased delivery of low 
molecular weight proteins to the glomeruli, and include conditions causing haemoglobinaemia, 
myoglobinaemia, and with increased levels of immunoglobulin light chains in certain cases of 
lymphoma and multiple myeloma. Post-renal causes of proteinuria include lower urinary tract 
diseases such as urinary tract infection, urolithiasis, or neoplasia of the lower urinary or genital tract 
(Lees et al., 2005). Once proteinuria has been determined to be renal in origin, PLN can then be further 
investigated by means of renal biopsy to establish the histopathological cause, although this is not 
always pursued clinically due to the risks of the biopsy procedure. Histopathological changes 
underlying PLN can include congenital glomerular malformations, acquired immune-mediated 
glomerulonephritis, reactive amyloidosis, and glomerulosclerosis (Littman et al., 2013). In many cases 
further screening to identify underlying conditions behind a secondary PLN, in particular in the case 
of immune-mediated glomerulonephritis, is also performed (Littman, 2011; Littman et al., 2013).  
1.2.3.2.1 Prevalence of thrombosis in PLN 
Thrombotic disease is a well-recognised potential complication of PLN, and in one post-mortem study 
was seen in 25% of cases (Cook and Cowgill, 1996). Other more recent prospective cross-sectional 
studies have reported a similar prevalence of thrombosis of between 6.6% and 27% (Donahue et al., 
2011; Lennon et al., 2013; White et al., 2016). As with IMHA, both venous thrombi and arterial thrombi 
have been reported. In human medicine, patients with nephrotic syndrome, a severe form of PLN, also 
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have an increased risk of thrombotic disease, with thrombi occurring in between 20 and 37% of adult 
patients (Singhal and Brimble, 2006)(Eneman et al., 2016). 
1.2.3.2.2 Pathophysiology of thrombosis in PLN 
As with IMHA the mechanism behind the thrombotic tendency in PLN is not fully understood, however 
classically has been largely attributed to abnormalities of secondary haemostasis due to AT deficiency. 
In an early case report of three dogs with PLN, AT levels were reduced to between 74 and 32% of 
normal, hypothesised to be due to increased urinary loss of this small protein. Likewise in human 
medicine, AT deficiency is seen in between 40 and 80% of patients, and some but not all studies have 
shown an association with deep vein and pulmonary thrombosis (Singhal and Brimble, 2006).  In recent 
years there has been a renewed interest in the pathophysiology of thrombosis in PLN, in particular in 
using viscoelastic testing to investigate additional abnormalities of secondary haemostasis alongside 
acquired AT deficiency (Donahue et al., 2011; Lennon et al., 2013; White et al., 2016). As yet limited 
work has been done in the veterinary field looking into any role the endothelium or platelets may play 
in thrombosis in PLN. In people however, evidence for additional mechanisms contributing the 
prothrombotic state has been found. These include endothelial cell injury, loss of other small 
anticoagulant proteins such as protein C alongside AT, and of particular interest for this thesis, 
increased platelet activation (Eneman et al., 2016; Singhal and Brimble, 2006). 
A recent study looked at TEG traces in dogs with PLN, and concurrently assessed antiplasmin, AT, D-
dimers, Factor VIII, fibrinogen, plasminogen, protein c and vWF levels. Of the 11 dogs with PLN, all had 
hypercoagulable TEG traces, with shorter R and K times and larger α, MA and CI values compared with 
normal controls. They were also found to have a significantly shorter PT, lower levels of AT, and higher 
levels of protein C and fibrinogen. However the same changes to the TEG, and AT and fibrinogen were 
seen in dogs with nonprotein-losing renal failure, raising the question of whether these changes alone 
are enough to explain the prothrombotic tendency seen in PLN (Donahue et al., 2011). Similarly, a 
study using kaolin activated TEG found 27 of 28 dogs with PLN to be hypercoagulable, having lower K 
and higher α and MA values, with no correlation between these values and the AT activity. They also 
found no significant difference in the AT activity between the 4 dogs with PLN with concurrent 
documented thrombosis, and the remaining 24 dogs without, however the number of dogs with 
thrombi may have been too small to detect a clinically significant difference.  Unlike the previous study, 
this one included both hypoalbuminaemic and normoalbuminaemic dogs with PLN, and found that 
both groups showed the same characteristics of hypercoagulability (Lennon et al., 2013). More 
recently, White et al similarly found no association between hypoalbuminemia and hypercoagulability 
as assessed by TF activated TEG in a larger population of dogs with PLN. They also found no correlation 
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between hypercoagulability on TEG and plasma AT activity. In this study the incidence of 
hypercoagulability as assessed by TEG was 89%, with an incidence of thrombosis of 6.6% (White et al., 
2016). Overall while multiple TEG abnormalities have been described, which of these are most 
important in predicting thrombotic risk is unknown. 
In the human field, while the alterations to the clotting cascade described above are widely described 
as the main abnormality driving thrombosis in patients with nephrotic syndrome, a number of 
different abnormalities in platelet function have also been discovered, and likely also contribute 
(Singhal and Brimble, 2006)(Eneman et al., 2016). These include evidence of increased platelet 
activation as shown in by increased in vitro platelet aggregation in response to various agonists, 
increased release of β-thromboglobulin and platelet factor 4, plus increased platelet surface 
expression of P-selectin and glycoprotein 53. While the exact mechanisms that drive this increased 
platelet activation are as yet unclear, associations with hypoalbuminemia, hypercholesterolaemia, 
and hyperfibrinogenaemia have all been described (Eneman et al., 2016). The degree to which these 
platelet alterations contribute to the risk of thrombosis is also unclear. In contrast to the volume of 
data available for humans, as yet in the veterinary field only very limited investigation of platelet 
activation in PLN has been performed. The first veterinary study investigating the role of platelets in 
PLN has suggested that hypoalbuminemia may be the main contributor to the increased thrombotic 
risk, via increased free plasma arachidonic acid causing increased platelet reactivity. It is worth noting, 
however, that although platelet hypersensitivity was found in two dogs using light aggregometry, both 
were additionally found to be infected with heartworm (Dirofilaria immitis)(Green et al., 1985). The 
adult worms of Dirofilaria live within the pulmonary vasculature, and have been found to induce 
coagulation dysfunction, although the mechanisms behind this are not fully elucidated (González-
Miguel et al., 2012). As such it is possible Dirofilaria rather than the PLE was behind the increased 
platelet activation in this study. Although there have been more recent studies evaluating the impact 
of uraemia on platelet function in dogs with CKD, which found evidence of increased platelet 
activation by means of surface P-selectin expression measurement, no investigators have looked 
further into the role of platelet function in dogs with PLN (Dudley et al., 2017).  Other suggested 
contributors to the hypercoagulable state in PLN are increased activity of clotting factors V, VII, VIII 
and X, increased vWF concentrations, and reduced plasminogen concentration. Overall, however, 
while PLN is accepted to be a prothrombotic condition, relatively little is known about the underlying 
prothrombotic mechanisms in dogs with PLN compared to those with IMHA.  
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1.2.3.3 PLE  
The final prothrombotic condition of interest, PLE, is a syndrome that can be seen with a variety of 
severe gastrointestinal disorders. It is characterised by increased protein loss through the intestinal 
tract, leading to hypoalbuminemia. The underlying mechanism behind PLE can vary from case to case, 
but always involves sufficient damage to the intestinal tract such that intestinal protein loss exceeds 
systemic protein synthesis. Diseases that can underlie PLE in dogs include chronic enteritis, intestinal 
lymphangiectasia and intestinal lymphoma, however inflammatory bowel diseases (IBD) are the most 
commonly seen cause. Protein losing enteropathy can present solely with gastrointestinal signs 
associated with the underlying intestinal pathology, but as with PLN can also present with signs of 
ascites or oedema due to hypoalbuminemia. In people PLE is more commonly caused by 
lymphangiectasia, rather than by IBD. However human IBD is similarly associated with thrombotic 
complications, and so is the closest disease for pathophysiological comparison (Craven and Washabau, 
2019). 
As with IMHA, there have been a number of studies looking for prognostic factors in canine patients 
with both PLE and IBD. Two disease severity scoring systems based on clinical signs and 
clinicopathological findings have been developed for IBD; the CIBDAI (canine IBD activity index) and 
CCECAI (canine chronic enteropathy clinical activity index) (Allenspach et al., 2007; Jergens, 2004). 
Notably multiple studies have identified hypoalbuminemia as a negative prognostic indicator in both 
IBD and in PLE specifically (Allenspach et al., 2007; Craven and Washabau, 2019; Gianella et al., 2017). 
Survival times for dogs with PLE are very variable, from a matter of weeks to several years. Eventual 
disease-associated death has been found to occur in around half of patients (Craven and Washabau, 
2019).  
1.2.3.3.1 Prevalence of thrombosis in PLE 
While thrombotic disease is a recognised risk in canine patients with protein losing enteropathy, the 
prevalence in dogs appears much lower than in either IMHA or PLN. There are, however, very few 
veterinary papers assessing the prevalence specifically, which has been reported as anywhere 
between 0 and 15% (Craven and Washabau, 2019). In one retrospective study of 92 dogs with PLE 
looking at potential prognostic factors, no mention was made of any occurrence of thrombosis. Fifty 
six of the 92 dogs in the study died over the 5 year study period, but reasons for death were not 
reported (Nakashima et al., 2015). In another study specifically investigating the prevelance of 
hypercoagulability in dogs with PLE using TEG, two of the 15 dogs (13%) had suspected 
thromboembolism (Goodwin et al., 2011). Equally, in a recent case series, 8 dogs with PLE and 
thromboembolism were seen across 3 referral hospitals over 3 years. For the one institute that an 
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overall incidence of PLE cases was available, this gave an incidence of thromboembolism in PLE cases 
of 7.1%. Of those 8 cases, six had PTE, two had splenic vein thrombosis and one had aortic 
thromboembolism (Jacinto et al., 2017).  
In humans, IBD patients have an approximately 2-fold increased risk of thromboembolism compared 
to healthy controls and patients with diseases other than IBD, with an incidence of thrombosis within 
the IBD population of approximately 1 in 100 (Grainge et al., 2010; Yuhara et al., 2013). Human 
patients are predominantly at risk of PTE and venous thromboembolism of the extremities. It has also 
been found that the risk of thrombosis correlates with disease activity, with patients having active 
flare-ups of disease at highest risk of thrombosis, with a relative risk in one study approximately 8 
times that of controls (Grainge et al., 2010; Scoville et al., 2014). 
1.2.3.3.2 Pathophysiology of thrombosis in PLE 
As thromboembolism is less common in canine PLE compared to IMHA or PLN, the mechanism of 
hypercoagulability in this disease has been less extensively investigated. As with PLN, abnormalities 
of secondary haemostasis have classically been understood to be the main mechanism.  This is 
predominantly due to reduced levels of coagulation factors, principally AT, secondary to enteric loss 
caused by the underlying intestinal pathology (Craven and Washabau, 2019; Goodwin et al., 2011). 
However again as with PLN, newer work in the human field is starting to suggest the role of 
inflammation, endothelial injury, and platelet activation may have been underappreciated 
contributors to thrombosis in PLE (Danese et al., 2004; Purnak and Yuksel, 2015; Senchenkova et al., 
2015).  
 In the only prospective veterinary study to date evaluating mechanisms of hypercoagulability, the 
investigators assessed TEG traces, PT, aPTT, AT activity, fibrinogen and D-dimers in a population of 15 
dogs with PLE. Compared with control dogs, all 15 PLE dogs had hypercoagulable TEG traces, with 
significantly decreased R, decreased K, increased α, and increased MA. The range of AT activity seen 
in the PLE dogs ranged from 46 to 121%, with 9 dogs having AT levels below the reference range of 
65-145%. The median AT from the group was borderline low, at 65%. The median fibrinogen 
concentration was moderately increased, while D-dimers were either normal or equivocal. PT and 
aPTT were normal in all but one of 9 dogs in which they were checked, and the only abnormal result 
was a mild prolongation of aPTT. There were no statistically significant associations detected between 
any of the TEG parameters and the other coagulation parameters (Goodwin et al., 2011). While overall 
this study confirmed that there is evidence of hypercoagulability in dogs with PLE, as with other 
prothrombotic diseases, the mechanism and degree of abnormality in individual affected dogs varies. 
In particular, the finding that some but not all of the dogs had reduced AT activity suggests that while 
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this may in part be responsible for the hypercoagulability seen, as was historically hypothesised, it is 
unlikely to be the only underlying mechanism. This is in agreement with a case series of 8 dogs with 
thromboembolism, in which hypoantithrombinaemia was only found in one of the two cases in which 
it was measured (Jacinto et al., 2017). Additional factors that have been suggested as contributors to 
the prothrombotic risk in canine PLE patients include hyperfibrinogenaemia, hyperhomocysteinemia, 
possibly in turn linked to cobalamin deficiency, and hypomagnesemia (Goodwin et al., 2011; Jacinto 
et al., 2017).  
In people, researchers have identified a number of abnormalities in coagulation and platelet activation 
that may contribute to the increased risk of thrombosis in IBD patients. These include increased levels 
of certain coagulation factors, increased circulating fibrinogen concentrations, decreased AT levels 
and decreases in inhibitors of coagulation such as protein C, protein S, and TFPI. Evidence of increased 
platelet activation associated with inflammation includes increases in the surface activation markers 
P-selectin, GP53, and CD40, alongside increased plasma levels of thromboxanes and β-
thromboglobulin (Purnak and Yuksel, 2015). A large number of environmental risk factors such as 
smoking, recent immobilisation and central catheter placement have also been associated with 
increased risk of thrombosis in IBD patients. Overall the pathogenesis of clots in these patients is not 
fully understood but is considered to be multifactorial; the situation is likely to be similar in our canine 
patients. To date, however, veterinary research into thrombosis in PLE has focused on secondary 
haemostatic abnormalities, and not on the roles of the endothelium and of platelets.  
1.3 Prothrombotic states in individual patients 
As outlined above, IMHA, PLN and PLE are all clearly associated with thrombosis at the population 
level, with a range of different predisposing factors for thrombosis proposed. However, within a 
population of diseased animals, different individuals with have different severities of change to each 
of the pathophysiological mechanisms that can lead to thrombosis. Thus each individual animal will 
have a different cumulative overall risk of a clot forming. When these aspects of haemostasis are only 
mildly abnormal, the individual may not have a clinically relevant increased risk of clot formation. 
However when multiple aspects are severely deranged, the animal may be at very high likelihood of 
forming a clot. This risk is also likely to change over time, affected by factors such as therapeutics and 
diagnostic investigations alongside the natural progression of the underlying predisposing disease 
itself. At times at which the individual is at high risk of thrombosis, they can be thought of as not only 
having a prothrombotic disease, but also as actively being in a prothrombotic state. In an ideal world 
we would be able to identify when patients are in a significant enough prothrombotic state that they 
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are at imminent risk of thrombus formation. This would potentially allow us to target antithrombotic 
therapy to those patients who are most at risk, with the aims of both reducing the incidence of 
thrombosis in the highest risk patients, and potentially sparing the lowest risk patients unnecessary 
antithrombotic therapy. This could in principle be achieved in three ways; firstly by individually 
assessing all the aspects of haemostasis and inflammation in each patient, to give a cumulative 
overview of the abnormalities present, secondly by identifying which single abnormality correlates 
most closely with the incidence of thrombosis in the specific disease and just evaluating that 
parameter, or thirdly by identifying a biomarker of overall thrombotic risk. At present, while a number 
of tests show some promise for utility in detecting a prothrombotic state in individual patients, they 
all have significant limitations.  
1.3.1 Detecting a prothrombotic state 
1.3.1.1 Platelet activation testing 
Given increased platelet activation has been documented experimentally in a number of 
prothrombotic diseases, investigators have looked into various ways of measuring platelet activation 
as potential markers of a prothrombotic state in individuals. At present few of these tests are clinically 
available, although some are starting to become accessible in larger referral hospitals. Broadly 
speaking there are two approaches to assessing platelet activation; firstly using platelet function 
assays that directly assess the clotting potential or reactivity of platelets in vitro in response to a range 
of agonists, and secondly by assessing markers of platelet activation that are either expressed on the 
platelet surface or secreted when platelets are activated.  
There are a number of methods available for platelet function testing, the majority of which are 
limited in availability to large specialist haematology laboratories, although in recent years attempts 
have been made to develop smaller bench-top analysers. While more accessible, and much less 
complex to run, these bench-top analysers tend to be far more limited in the information they can 
provide. Classically platelet function testing has been by light transmission aggregometry (LTA). This 
still represents the gold standard for platelet function testing in human medicine and is widely used 
in reference laboratories. LTA requires platelet rich plasma, generated by centrifugation of 
anticoagulated whole blood, and measures platelet aggregation in response to addition of a platelet 
agonist, via analysis of light transmission through the sample as aggregation occurs. The agonist 
chosen depends on the specific reason for analysis (for example diagnosis of thrombocytopathia, or 
for therapeutic drug monitoring). Due to the specialised equipment and training required for this test, 
LTA is confined to large human medical reference laboratories, and at present is not available at 
veterinary reference laboratories within the UK. As such Its use in veterinary medicine is largely 
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confined to research studies. A variant on LTA is whole blood impedance aggregometry (WBA). One 
of the advantages of this method is that it uses anticoagulated whole blood, so both requires less 
sample processing than LTA, and has been argued to evaluate coagulation in a more physiological 
setting than in platelet rich plasma. WBA works by measuring the change in resistance between two 
electrodes as platelets aggregate between them. Again, a range of different agonists can be used to 
induce platelet aggregation depending on the reason for testing. Like LTA, WBA cannot be used in a 
clinic point-of-care setting, however in human medicine it can be used in a near-patient setting, 
primarily in large hospital laboratories. As such, while several important studies assessing platelet 
function in veterinary medicine have used this technique, its use is confined to a research setting. 
Because of the complex technical requirements for LTA and WBA, researchers have tried to develop 
similar but simpler assays. These include the Multiplate analyser, VerifyNOW analyser, the 
Plateletworks system, vasodilator-stimulated phosphoprotein (VASP) phosphorylation assay, and the 
Platelet Function Analyser-100 (PFA-100) and Platelet Function Analyser-200 (PFA-200)(Saati et al., 
2018). These are all based on similar principles of measuring changes in sample platelet number, light 
transmission, or electrical impedance following addition of platelet agonists, to assess how easily the 
platelets within a sample aggregate. Of these, only the PFA-100 and PFA-200 are true bench-top 
analysers. A few veterinary studies have used the PFA to assess platelet reactivity in patients with 
prothrombotic conditions, however no evidence of hyper-reactivity was seen using this tool in dogs 
with neoplasia, hyperadrenocorticism and cardiac disease (Clancey et al., 2009; Eberle and Mischke, 
2010; Jeffery et al., 2016; Kol et al., 2013) . While some studies using the other laboratory-based assays 
have been performed in veterinary medicine, they are only just starting to be available as day-to-day 
tools in larger referral practices.  
In routine veterinary practice, the only readily available potential marker of platelet activation is the 
MPC, which can be measured on automated haematology analysers readily available to veterinary 
practices (Macey et al., 1999). Recently there has been a renewed interest in MPC as a possible marker 
of platelet activation and prothrombotic risk in various situations, including canine IMHA, DIC, 
neoplasia, sepsis and certain parasitic infections (Goddard et al., 2015; Piek et al., 2011; Smith et al., 
2014; Zoia et al., 2018) . MPC has been shown to be a possible prognostic indicator in IMHA, although 
as yet no studies have looked specifically into its utility for predicting thrombotic risk (Zoia et al., 2018). 
The second approach to evaluating the degree of platelet reactivity is to measure various markers of 
activation. These markers can be substances released from platelet granules on activation, substances 
synthesised and excreted only when platelets are activated, or molecules expressed on the platelet 
surface in greater numbers following activation.  The most commonly used measures are P-selectin 
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and metabolites of thromboxane. P-selectin levels are most commonly measured by flow cytometry. 
This technique uses a variety of antibodies and dyes to differentiate between blood components such 
as leucocytes and platelets, and to assess the level of a wide range of different proteins expressed on 
cell surfaces. In addition to assessment of baseline levels, platelet surface markers including P-selectin 
can be measured following addition of agonists such as ADP or Phorbol myristate acetate (PMA), to 
assess the change in surface protein expression as a marker of platelet reactivity. Flow cytometry can 
also be used to evaluate for other blood components such as platelet-leucocyte aggregates and 
microparticles, which have been suggested in some studies to be more sensitive and reliable than 
surface proteins such as P-selectin as markers of platelet activation (Wills et al., 2006). An additional 
limitation of P-selectin specifically is that it is both rapidly shed from the platelet membrane surface 
following activation and is also involved in leucocyte-platelet binding and aggregation. The latter 
feature means some surface P-selectin on activated platelets in samples from clinical patients could 
already be pre-bound by circulating leucocytes, meaning it will not be free for binding and detection 
by the immunofluorescent antibody used for flow cytometry. As such there is some debate over 
whether P-selectin is the best surface marker of platelet activation, or whether other additional or 
alternative markers should be explored (Wills et al., 2006).  While at present flow cytometry 
measurement of platelet surface markers is a research tool, and not clinically available, flow cytometry 
itself can already be used clinically for investigating surface molecule expression of circulating 
leucocytes, so in theory a similar service could be established for platelets, should studies show clinical 
utility.  
Finally, measurement of metabolites of activated platelets has been investigated as a potential marker 
of prothrombotic risk. The predominant metabolic pathway evaluated for this purpose is the 
thromboxane A2 pathway. Thromboxane A2 is produced by the enzyme cyclooxygenase 1 (COX-1) in 
activated platelets and then released into the circulation. It is a potent platelet agonist, recruiting and 
activating further platelets by binding to surface thromboxane receptors, and so acts as a major 
positive feedback loop for platelet activation. This pathway has been used to evaluate platelet 
activation in several ways. Firstly, direct measurement of levels of thromboxane and its downstream 
metabolites in plasma and urine have been investigated. Secondly, expression levels of the COX 
enzyme itself within platelets can be measured, again by monoclonal antibody labelling and detection 
using flow cytometry. These approaches have been used in a number of veterinary and human studies 
assessing the impact of the COX-inhibitor drug aspirin (Dudley et al., 2013). To date, however, very 
little work has been done in veterinary patients evaluating the potential of thromboxane metabolites 
as markers of platelet activation, or as biomarkers for thrombotic risk. As the major focus of this thesis, 
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thromboxane metabolite measurement and its possible roles in thromboembolic disease is expanded 
upon in a subsequent section below. 
1.3.1.2 Viscoelastic testing 
The assays that have received the most attention recently for their potential utility to identify a 
prothrombotic stage are the viscoelastic assays of global coagulation; Thromboelastography (TEG) and 
ROTEM. These viscoelastic techniques aim to provide data on all aspects of haemostasis, from the 
time to clot initiation to measures of fibrinolysis. As such these methods are said to give a measure of 
‘global’ haemostasis, being able to assess for both hypercoagulability and hypocoagulability as well as 
platelet factors. It has also been suggested it may be better for predicting the overall risk of thrombosis 
in patients with multifactorial causes for being prothrombotic, as it allows the platelet and clotting 
factor components of coagulation to interact, rather than assessing them independently as with 
classical coagulation tests. This is felt to represent a more global view of clotting, including more of 
the complex interactions between clotting and cellular surfaces explored by the cell-based model of 
haemostasis. The drawback, however, is that they are still ex-vivo tests, and so cannot take into 
account the role of the endothelium, or of blood stasis (Donahue and Otto, 2005). 
Practically, TEG involves incubating anticoagulated whole blood in a sample chamber with an 
oscillating pin suspended in the centre. The basic principle is that clot formation in the whole blood 
sample slows and then stops the vibration of a central pin, with the magnitude of the vibrations over 
time being recorded and produced as an output trace. Various measures can be taken from this trace, 
including the time for clotting to start, the speed at which a clot forms, the overall strength of that 
clot, and the speed with which the clot is then broken down. Common measurements used are the 
lag time before the clot starts to form (‘reaction time ‘R’), the rate at which clotting occurs (K), the clot 
formation angle (α), the maximal amplitude of the trace (MA), which represents clot strength, and the 
rate of amplitude reduction as a measure of fibrinolysis (Figure 2). These different aspects of the trace 
are affected to varying extents by the different aspects of the clotting cascade and platelet function, 
so can be used to a degree to help determine the origin of hyper- or hypo-coagulability detected. For 
example, the reaction time R has been found to be principally a measure of the speed of the reactions 
of the intrinsic pathway, meaning it is affected by alterations to the concentrations of factors VIII, IX, 
XI and XII. The rate of clotting to a predefined clot strength, K, is affected by both platelet numbers 
and function, alongside the levels of fibrinogen, thrombin, factor VII, and also by the haematocrit. The 
strength of the clot formed, represented by MA, is also affected by platelet count, function, 
haematocrit, fibrinogen and thrombin, but also by factor XIII.  
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As discussed in more detail for IMHA, PLE and PLN specifically below, viscoelastic tests have been used 
to identify a hypercoagulable state in a number of canine diseases, including hyperadrenocorticism , 
IMHA, PLN, neoplasia, and in critically ill dogs with a range of conditions (Fenty et al., 2011; Goggs et 
al., 2012; Hamzianpour and Chan, 2016; Pace et al., 2013; Sinnott and Otto, 2009). These studies use 
a range of parameters generated by the TEG to define 'hypercoagulability', and as of yet there is no 
consensus as to which are the most useful or appropriate.  In addition, none of these studies correlate 
the finding of a hypercoagulable TEG tracing with the occurrence rate of thrombosis in the population 
involved. As previously discussed, the only study to attempt this found no association between any of 
the TEG parameters and the incidence of thrombosis in the dogs at necropsy up to 7 days later 
(Thawley et al., 2016). In human medicine a recent systematic review found some evidence that TEG 
could be used to predict the risk of thromboembolism in post-operative surgical patients, however 
there was a large degree of variability in the sensitivity (0 – 100%) and specificity (62-92%)(Dai et al., 
2009). As in the veterinary world, there were also different definitions of what constituted a 
hypercoagulable tracing used in the different individual studies reviewed. At present, viscoelastic tests 
may represent a promising avenue for further research into predicting thrombotic risk in veterinary 













Legend: Figure 2A: A normal TEG trace. Figure 2B: A TEG trace with changes consistent with hypercoagulability 
including shortened R, shortened K, increased α and increased MA. Figure 2C: A TEG trace with changes 




As discussed above the specificity of D-dimers for the presence of a detectable thrombus tends to be 
low, with increased D-dimers being seen in a variety of conditions. However it has been speculated 
that this may be due to D-dimers actually being very sensitive for a prothrombotic state, in which 
thrombi are being partially formed, but fibrinolysis and coagulation are occurring in balance, so 
thrombi of a clinically relevant size are never formed (Jeffery et al., 2016). Supporting this idea are a 
number of population-level human studies in which elevated D-dimers are associated with an 
increased long-term risk of subsequent venous thrombosis.  One such study found an overall increased 
adjusted hazard ratio of 3.2 for venous thromboembolism (either DVT or PTE) in the patients in the 
initial highest quartile of D-dimer values (0.51- 20 ug/ml) compared to the lowest quartile (0.01-0.14 
ug/ml) in over 12000 participants over a 17-year study period (Folsom et al., 2015).  Whether this 
relationship seen at the population level also applies to D-dimers as a predictor of thrombotic risk in 
an individual human patient is less clear. In veterinary medicine, D-dimers have to date only been 
evaluated for detecting existing thrombosis; to the authors knowledge there are no longitudinal 
studies looking at future risk of thrombosis based on D-dimer levels, either in diseased or healthy 
canine populations. Future studies in this area may help to evaluate D-dimers as markers of 
prothrombotic tendencies, although differences in performance and agreement between different 
canine D-dimer assays are a significant obstacle that need to be addressed to make this feasible 
(Jeffery et al., 2016).   
1.3.1.4 Classical secondary haemostatic tests 
Of the classical tests of coagulation, while any association with the presence of a gross thrombus is 
doubtful, PT and aPTT have attracted recent attention as possible indicators of hypercoagulability. 
Historically in veterinary medicine, while prolongation of the clotting times PT and aPTT have been 
associated with hypocoagulability and bleeding tendencies, shortening of both the PT and aPTT have 
been thought to be of no clinical significance. In human medicine, however, a shortened aPTT has 
been associated with an increased risk of long-term venous thromboembolism. In a recent study of 
over 13,000 patients over 13 years, patients with a starting aPTT in the lowest quartile had a 2.4x 
higher risk of venous thrombosis over those with aPTT in the highest quartile, although the incidence 
of venous thrombosis in the population overall was low (Zakai et al., 2008). A relationship between 
degree of shortening of the aPTT and the risk of venous thrombus has also been identified, with the 
adjusted odds ratio for VTE increasing with decreasing aPTT ratio (Tripodi et al., 2004).  
In the veterinary field, a recent retrospective study found that dogs with shortened PT or aPTT had a 
significantly higher overall incidence of thrombosis compared to controls (70% vs 39%). Suspicion of 
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PTE specifically was also seen more commonly in cases (61%) as compared with controls (9%), and of 
all the dogs with suspected PTE, 88% had a shortened PT or aPTT (Song et al., 2016). Whether the 
shortened PT and aPTT in this study reflect an underlying hypercoagulable state, or the presence of a 
thrombus itself and active consumption of clotting factors is debatable. As this is the only study to 
date assessing the relevance of shortened PT and aPTT in dogs, further studies evaluating this possible 
link with hypercoagulability are warranted before these clotting times can be considered useful in 
helping detect a prothrombotic state in individual patients.  
1.3.1.5 Other Novel markers 
Given the limitations in our currently clinically available tests to predict which patients are 
prothrombotic, there is unsurprisingly a lot of ongoing research in this area in both human medicine 
and veterinary medicine, and a number of novel potential markers have been identified for future use. 
In humans, serum levels of antiphospholipid antibodies have been shown to be predictive of venous 
thrombosis risk in certain situations (Lijfering et al., 2010). Canine antiphospholipid antibodies can be 
measured by ELISA, and so could relatively easily be offered as a clinically available diagnostic test by 
laboratories already offering other canine ELISA based tests. However an initial study looking at levels 
in healthy dogs, as compared with sick dogs without thrombosis, and dogs with either IMHA, 
spontaneous thrombosis, or hyperadrenocorticism showed no evidence of a difference in antibody 
prevalence between the groups to suggest use as a predictor of thrombotic risk in dogs (Miller et al., 
2012). As such at present antiphospholipid antibodies do not appear to be a clinically useful measure 
of individual patient’s prothrombotic state.  
Circulating microparticle levels have also recently been identified as potentially useful markers of 
prothrombotic tendency, both in the human and veterinary fields. Microparticles can be measured in 
two ways; either by flow cytometry which uses antibodies to quantify the number of microparticles of 
different cells of origin in a sample, or by functional assays, which may better assess the physiological 
relevance of the detected microparticles but does not quantify the number present nor identify their 
cell of origin (Jeffery et al., 2016). In human medicine, several prospective studies, particularly in 
patients with neoplasia, suggest blood levels of tissue-factor bearing microparticles may predict risk 
of venous thrombosis. Whether microparticles have the same predictive use in human patients that 
develop venous thrombi without an underlying neoplasia is still unclear however. In a recent study, 
microparticle levels measured by flow cytometry were compared between patients with newly 
diagnosed venous thrombi and healthy controls. They showed a significantly higher median 
microparticle level in the patients with thrombi, and a linear association between the level of 
microparticles and the risk of thrombi, although there was a significant overlap between the level of 
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microparticles seen in the two populations (Bucciarelli et al., 2012). Microparticles have also been 
investigated for association with thrombosis in a number of veterinary studies, as outlined for IMHA 
in section 1.2.3.1.2 above,  but have not to date been evaluated as a predictor of future thrombosis in 
individual patients. 
1.3.2 Detecting a prothrombotic state in patients with IMHA 
Of the tests of platelet activation outlined above, only platelet surface markers, microparticle levels, 
and MPC have to date been evaluated in dogs with IMHA. Platelet surface P-selectin expression has 
been found to be increased in dogs with IMHA compared to healthy controls, but interestingly the 
degree of increase is not consistent across the IMHA dogs. In one study 15 of the total 20 IMHA dogs 
had higher than reference P-selectin levels when the dogs were assessed individually. Additionally, 
the percentage of individual platelets within a single dog showing increased P-selectin was very 
inconsistent, varying from 12.4 to 43.6%. The authors further investigated whether there was any 
correlation between the P-selectin expression and the clinical occurrence of thromboembolism. Seven 
of the dogs had clinical signs suggestive of thromboembolism, but there was no difference in the mean 
P-selectin expression between those dogs with suspected thromboembolism and those without 
(Weiss and Brazzell, 2006b). As such it is currently unclear whether platelet surface marker expression 
is likely to be a useful tool clinically for predicting thrombotic risk in individual veterinary patients. 
Logically, it seems likely that a panel of surface markers beyond just P-selectin expression may give 
more information than a single marker, as is the situation for flow cytometry analysis of leucocyte 
surface molecules. At present, the only clinically available measure of platelet activation is platelet 
MPC. Only one study has evaluated MPC in clinical IMHA cases so far, but the authors found a 
significant association between MPC and outcome, with a decrease in MPC of 1 unit associated with 
a 16% increased risk of death. They did not, however, evaluate for any association with thrombosis 
itself (Zoia et al., 2018). As such, it remains to be seen whether MPC may have future utility in this 
role.  
The viscoelastic test TEG is probably the most clinically useful test of hypercoagulability in dogs with 
IMHA currently, although access to the test is currently limited to certain large veterinary hospitals. In 
the existing studies evaluating TEG abnormalities in IMHA dogs, some associations with survival in 
individual dogs have been found. Interestingly, whether relatively hypercoagulable, hypocoagulable, 
or normocoagulable traces are linked with worse prognosis is variable between studies. In a study 
using a calculated coagulation index (CI), authors found a normal CI was significantly associated with 
decreased survival compared with having a hypercoagulable CI. None of the 6 dogs with normal CI 
survived, while 56% of the hypercoagulable dogs survived. Overall 76% of the individual TEG 
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parameters were hypercoagulable, however there was no statistical association between any of these 
4 TEG parameters and survival status (Sinnott and Otto, 2009). In contrast, more recently, using 
standard TEG parameters, Goggs et al found that dogs with IMHA were significantly hypercoagulable 
compared to controls, but also found a significant association between increased MA and survival, 
with relative hypocoagulability at admission being a negative prognostic indicator. It was hypothesised 
that this relative hypocoagulability was consistent with a consumptive coagulopathy, so explaining the 
link to a poorer prognosis.  They also tracked the TEG changes over the course of treatment in these 
dogs, and found that over the first 5 days the R and K values significantly increased, while the MA 
value decreased, overall consistent with worsening hypercoagulability (Goggs et al., 2012). Notably 
none of these studies assessed for associations between TEG variables and the subsequent incidence 
of thrombosis in these patients, so at present while we know there are potential associations with 
survival, we do not yet know whether TEG can be used to help quantify which patients are in a 
prothrombotic state, and so at increased risk of thrombosis.  
Equally, of the other research methods that have identified abnormalities that could contribute to 
thrombosis in IMHA, including microparticle analysis, intravascular TF expression, circulating NETs 
levels, and PS expression, none has as yet been evaluated for associations with the occurrence of 
thrombosis in clinical patients. Additionally, at present none of these methods are easily accessible to 
clinicians in practice, even in academic referral institutions. Overall while there is a strong body of 
evidence that numerous different abnormalities can contribute to the prothrombotic tendency in 
IMHA, there is limited information on how we can test for thrombotic risk and the presence or absence 
of a prothrombotic state in individual patients within the clinic.  
1.3.3 Detecting a prothrombotic state in patients with PLN 
As outlined above, the majority of work looking at underlying causes for thrombosis in canine PLN 
patients has focused on the role of AT deficiency. While a number of studies have identified low AT 
levels in dogs with PLN, fewer have sought to assess an association between AT levels and the 
subsequent incidence of thrombosis in individual dogs. The one study to attempt to do this found no 
significant difference in AT levels between the 4 PLN dogs with concurrent thrombosis, and the other 
24 PLN dogs in the study (Lennon et al., 2013). The authors did comment, however, that the number 
of dogs with thrombi may have been too small to detect a clinically significant difference. Likewise, 
where researchers have investigated TEG abnormalities in dogs with PLN, no attempt to correlate the 
findings with the occurrence of thrombosis have been made. Authors of one study noted that the 
incidence of hypercoagulability as assessed by TEG was 89%, while the prevalence of thrombosis in 
the group was 6.6%, but no further analysis was performed (White et al., 2016). Overall while we are 
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starting to identify additional prothrombotic abnormalities present in dogs with PLN, we are a long 
way from establishing which are most clinically relevant, and which may have potential to be used as 
biomarkers in individual patients. Additionally, very little is currently known about whether significant 
platelet activation is present in these patients.  
1.3.4 Detecting a prothrombotic state in patients with PLE 
Of the three diseases, least is known about the overall mechanisms that make dogs with PLE 
prothrombotic, likely because of the lower prevalence of thrombosis compared to IMHA and PLN. In 
the single study evaluating haemostatic abnormalities in dogs with PLE, all 15 dogs were 
prothrombotic based on TEG, but no ongoing follow-up to document the incidence of thrombosis in 
those patients was reported (Goodwin et al., 2011). Likewise in people, while a wider array of 
haemostatic abnormalities affecting both coagulation and platelet function have been identified, very 
little is known about how they correlate with risk of thrombosis, or which are most useful for detecting 
a prothrombotic state in individual patients (Giannotta et al., 2015; Purnak and Yuksel, 2015).  
1.4 Urinary thromboxanes 
As outlined above, platelet activation is a key factor in thrombus formation, however the main ways 
of monitoring platelet activation are only available in research settings. As urine is an easy sample to 
collect from clinical cases, measurement of urinary thromboxanes as a marker of thromboxane 
production may represent an easily accessible marker of platelet activation, and potentially of 
thrombotic risk. 
1.4.1 Thromboxane physiology and measurement 
As mentioned above, the phospholipase A2 pathway is a key platelet metabolic pathway, which plays 
a key role in platelet activation through generation of thromboxane A2. As such, measurement of 
thromboxane A2 and its downstream metabolites has been widely investigated as a potential marker 
of platelet activation and thrombotic risk in human medicine, and to a more limited degree in 
veterinary medicine. In terms of physiology, Thromboxane A2 is produced from arachidonic acid via 
the phospholipase A2 pathway. An overview of this pathway is shown in Figure 1. The arachidonic acid 
is released from the platelet cell membrane by phospholipase A2, which is activated by the increase in 
intracellular calcium concentrations that results from activation of the myriad of platelet surface 
receptors by their agonists. The two other key enzymes in the synthesis of thromboxane are 
cyclooxygenase (COX) and thromboxane synthase. Once produced, thromboxane A2 is released from 
the platelets into serum, but is extremely unstable, and rapidly breaks down to form thromboxane B2. 
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In turn thromboxane B2 is then metabolised to two products; 11-dehydrothromboxane B2 (11-dTXB) 
and 2-3-dinor-11-dehydrothromboxane B2. These products are both excreted unchanged in urine, 
with 11-dTXB being the most abundant.  
Studies have shown that urinary 11-dTXB excretion is a good estimate of thromboxane production in 
both people and in dogs (Yamanaka et al., 1993). In early studies 11-dTXB was measured by gas 
chromatography and mass spectrometry, but since the 1990’s enzyme immunoassays have been more 
commonly used (Reinke, 1992) . The enzyme-based ELISA assays have been validated for use in both 
human and canine urine (Lellouche et al., 1990; Yamanaka et al., 1993). Urinary 11-dTXB is usually 
normalised to urine creatinine concentration to give a urine 11-dTXB-to-creatinine ratio (u11-dTXB:Cr). 
Urinary 11-dTXB has also been shown to be stable at room temperature for up to 6 days after 
collection (Pagliaccia et al., 2014). While serum thromboxane B2 can be measured, the levels can be 
artifactually increased by further platelet activation ex-vivo during venepuncture or in blood collection 
tubes. As such, u11-dTXB:Cr has the advantage of being a more reliable measure of in vivo 
thromboxane levels, since ex-vivo generation of thromboxane does not occur in urine. 
It is important to note that both COX and thromboxane synthase can be expressed in a number of cell 
types other than platelets, and that several extra-platelet sources of thromboxane have been 
identified, including the endothelium and activated inflammatory cells. Under normal physiological 
conditions, between 70 and 80% of human serum thromboxane is produced by platelets, with 
monocytes being the main extra-platelet source. The proportion of thromboxane produced by 
monocytes has been shown to be increased in various inflammatory states, in particular by 
inflammation associated with atherosclerotic plaques (Catella and Fitzgerald, 1987). Since 
thromboxane is both produced by platelets, and causes platelet activation via surface thromboxane 
receptors, it has the potential to be useful as a marker of platelet activation for two reasons; firstly as 
in the absence of significant levels of production from extra-platelet sources thromboxane represents 
a measure of the degree of metabolic platelet activity; secondly as one of the direct causes of platelet 
activation, thromboxane concentration can be taken as a marker of the level of stimulation of platelets, 
irrespective of the source of thromboxane. As such, urinary thromboxane measurement may have 
utility in detecting prothrombotic states in which platelet activation is occurring.  
1.4.2 Urinary thromboxanes in human medicine 
In human medicine, u11-dTXB:Cr is a well-established marker of platelet activation, and has been 
widely evaluated as a biomarker for risk of future thromboembolic disease. It is increased in multiple 
conditions in which there is an increased thrombotic risk, including atherosclerosis, acute coronary 
syndrome, stroke, heart failure, atrial fibrillation, venous thromboembolism, diabetes, 
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hypercholesterolaemia, essential hypertension, chronic kidney disease, rheumatoid arthritis, systemic 
lupus erythematosus and IBD. While it is not yet used on a day-to-day clinical basis, urinary 
thromboxanes have been proposed as a future tool to guide the need for antiplatelet 
prophylaxis(Neath et al., 2014). A u11-dTXB:Cr level above a certain cut-off has already been found to 
be prognostic for the risk of repeat thrombotic cardiac events in patients with existing coronary artery 
disease on treatment with aspirin (Vasudevan et al., 2018). 
Aside from being a marker of platelet activity, urinary thromboxanes have also been used to evaluate 
the impact of aspirin therapy on COX inhibition. Aspirin irreversibly acetylates COX and so inhibits its 
function in a variety of cell types. In platelets, this leads to reduced function and so reduced 
thromboxane production for the duration of the platelet’s lifespan, and so an anti-thrombotic effect 
clinically. The antithrombotic effect of aspirin has been found to be highly variable in people, with 
some patients being identified as ‘poor responders’ to therapy. Since urinary thromboxane production 
is dependent on COX activity, u11-dTXB:Cr has also been used as a tool to evaluate patients’ response 
to aspirin therapy (Patrono, 2003).  
1.4.3 Urinary thromboxanes in veterinary medicine 
In veterinary medicine, there have been more limited studies investigating the utility of u11-dTXB:Cr 
in a clinical setting. The first study evaluating it in dogs looked at its potential utility as a marker of 
reperfusion of ischaemic gut in dogs with gastric dilation volvulus (GDV). They found both higher u11-
dTXB:Cr levels in dogs with GDV overall compared to healthy controls, and higher postoperative levels 
in those dogs that had complications than those that did not. The preoperative levels were not, 
however, predictive of outcome (Baltzer et al., 2006). u11-dTXB:Cr has also been used in several 
studies in healthy dogs as a tool for assessing the effects of aspirin at inhibiting COX. These studies 
have found that aspirin does decrease u11-dTXB:Cr, as would be expected with successful COX 
inhibition, but that the effect is very variable, in some studies requiring dosages of 10mg/kg/day (Hoh 
et al., 2011). Other than the study in dogs with GDV, however, to the authors knowledge there have 
been no studies looking at u11-dTXB:Cr in naturally diseased dogs. As such nothing is known as to 
whether u11-dTXB:Cr may be increased in similar situations in dogs to those it is increased in in people, 




1.5 Aim of this study 
As has been outlined in this introduction, IMHA, PLN and PLE are three commonly seen canine diseases 
with frequent thromboembolic complications. Research so far has identified a number of 
pathophysiological abnormalities that underlie this prothrombotic tendency. To date, there is 
unequivocal evidence that increased platelet activation plays a role in patients with IMHA, but limited 
work evaluating a role in PLE and PLN. Overall it is likely that a combination of abnormalities to platelet 
function, secondary haemostatic proteins, and endothelial function contribute to the overall degree 
of prothrombotic state in an individual patient. Equally it is likely the level of thrombotic risk varies 
between patients, and within the same patient over the time course of a particular disease. At present 
we have very limited means of testing patients for a prothrombotic state, and it is unclear whether 
the results of the tests we do have can be translated to a clinically relevant risk of thrombus formation. 
Identifying new biomarkers of thrombotic risk that can be easily measured in clinical patients would 
allow further longitudinal research to correlate test results with the incidence of thrombosis in such 
patients. Should a reliable biomarker of thrombotic risk be identified, it would enable us both to better 
stratify patients as to their individual risk, and to help judge whether any antithrombotic therapy 
prescribed is effective. Urinary thromboxanes have been identified as measures of platelet activation 
and are easily measured via ELISA. More importantly in human medicine they have been found to 
correlate with the clinical risk of thrombosis in various situations. They have not, however, to date 
been assessed for utility in this role in canine patients.  
Given platelet activation has been well documented in patients with IMHA, this study’s first hypothesis 
is that urinary thromboxanes as measured by u11-dTXB:Cr are increased at baseline in dogs with IMHA 
compared to normal controls. The second hypothesis is that since thromboembolic disease is a major 
cause of mortality in dogs with IMHA, u11-dTXB:Cr will be correlated with survival outcome, or other 
known markers of disease severity in these patients. A third hypothesis is that since urinary 
thromboxanes are markers of platelet activation, and platelet activation appears to be important in 
the pathogenesis of thrombosis, u11-dTXB:Cr will also be higher in dogs with thromboembolic 
complications of IMHA compared to those without. The final hypothesis for the IMHA patients is that 
the thrombotic risk varies over the course of their disease, and so a final aim is to describe the change 
in u11-dTXB:Cr over the first 6 weeks of treatment by serial measurement at predetermined time 
intervals.  
For both PLN and PLE, there has been very limited investigation into the role of platelet activation in 
thrombosis. However there is evidence from the human field that platelet activation occurs in patients 
with similar diseases, and may be an important contributor to the prothrombotic state in some of 
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these patients. The final two hypotheses for this study are that platelet activation is similarly 
important in veterinary PLN and PLE patients, and so urinary thromboxanes, as measured by u11-




2 Materials & Methods 
2.1 Study design 
The main part of this study was a prospective case-control design. Based on a power calculation using 
u11-dTXB:Cr levels reported in a previous study of pre-neuter control dogs and dogs with gastric 
dilation-volvulus , an α of 0.05 and a β of 0.9, we aimed to recruit a minimum of 6 normal dogs and 6 
‘diseased’ dogs for each of IMHA, PLN and PLE groups for the basic hypotheses. For the second and 
third hypotheses, as the range of urinary thromboxane levels likely to be seen in the IMHA dogs was 
unknown, we aimed to recruit 20 dogs based on reported mortality rate for IMHA of approximately 
50%, to give 10 IMHA dogs in each survival group. We estimated based on recent experience that the 
SAH sees between 10 and 15 canine IMHA cases per year, so planned to recruit cases over a 2 year 
period.  
2.2 Ethical considerations 
This study was approved by the University of Glasgow School of Veterinary Medicine Research ethics 
committee (application 49a16). For the first part the study involved free-catch urine sample collection 
from all groups of dogs, unless a cystocentesis sample had already been collected as part of the routine 
work-up, in which cases any excess sample was used. For the second and third parts of the study, most 
clincopathological data were obtained as part of the standard clinical evaluation of cases. Where 
possible, residual EDTA blood or serum samples were stored at the time the case was seen, so if 
required for the study extra biochemical tests or C-reactive protein (CRP) could be run at a later date. 
2.3 Study populations 
2.3.1 Control group 
2.3.1.1 Selection criteria 
Control dogs were healthy animals owned by staff and students at the Small Animal Hospital. They 
were judged to be healthy based on owner history, clinical examination, and routine urinalysis. Dogs 
were excluded if there were abnormalities on clinical examination, if they had been vaccinated in the 
preceding 2 weeks, or if they were on long-term medications other than routine endo- and ecto-




2.3.1.2 Data recording and sample collection 
Signalment data and health information were collected by means of an owner questionnaire. All 
normal dog urine samples were collected by the owners by free catch.  
2.3.2 IMHA group 
2.3.2.1 Selection criteria 
Dogs with primary immune-mediated haemolytic anaemia were prospectively recruited. Most cases 
of IMHA present to the referral hospital as emergency cases with anaemia, so were expected to be 
easily identifiable for possible study inclusion. Dogs were excluded if they had been on 
immunosuppressive therapy from their referring veterinarian for over 48 hours at presentation. 
Diagnostic criteria for IMHA were anaemia with HCT <37%, plus the presence of two of three criteria: 
spherocytosis, positive Coombs test, or positive in-saline agglutination. Dogs were classified as having 
primary IMHA following exclusion of possible triggers for secondary IMHA; this involved a medical 
work up as felt indicated by the primary case clinician, and included abdominal and thoracic imaging, 
further biochemical analysis, urinalysis and infectious disease testing based on travel history. Although 
the recent ACVIM guidelines for diagnosis of primary IMHA were not published at the inception of this 
study, these criteria are in line with those recommendations (Garden et al., 2019).  
2.3.2.2 Data recording and sample collection 
Haematology, serum biochemistry, CRP and fibrinogen were measured at admission as part of the 
standard case investigation. Depending on the timing of case presentation, the haematology was 
either run directly at the reference laboratory (ADVIA 120, Siemens, Frimley, UK), or performed on the 
in-house analyser (Idexx Catalyst). Similarly, biochemistry was either run at the reference laboratory 
(Dimension XPAND, Siemens, Frimley, UK), or on the in-house analyser (Idexx Procyte). For platelet 
count, where an automated machine count was not provided due to platelet clumping, clinical 
pathologists reported a comment on approximate count from blood smear examination. These 
comments were translated into an estimated platelet count for statistical analysis as per Table 3. The 
presence or absence of spherocytosis as judged by a clinical pathologist, and results of slide 
agglutination and direct Coombs tests were also recorded. Urine was collected by free catch within 
24h of admission unless cystocentesis was required for the clinical work-up. Each urine sample used 
for urinary thromboxane measurement was also analysed routinely, and the results of dipstick and 
sediment exam recorded. For disease severity scoring, CHAOS score, total bilirubin (T.bil), creatinine, 
urea, ALT, CRP, fibrinogen, HCT, PLT, and ASA score at admission were recorded when available for all 
cases. CHAOS scores were calculated as previously described (Goggs et al., 2015)(Whelan et al., 
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2006)(Table 2). ASA scores were recorded at admission by either the primary case clinician, or an ECC 
clinician assisting with case management. A coagulation profile was requested for all cases, to include 
PT, aPTT, FDP, D-dimers and fibrinogen levels. Treatment protocols were recorded for all cases, 
including dosages of immunosuppressive and anti-thrombotic medications. All therapeutic decisions 
regarding patient care were made by the primary case clinician as is normal hospital policy; there was 
no standardisation of therapy as part of this study. 
Table 3: Blood smear platelet comment interpretation 
Blood smear 
 platelet comment 
PLT count range 
estimate (x10^12/l) 








Abbreviations: PLT, platelet. 
 
Outcome measures were recorded as survival to hospital discharge, survival to 30 days following 
admission, and survival to 90 days following admission. Situational details regarding death were 
recorded for all cases, including whether dogs died naturally or were euthanised.  If surviving dogs had 
returned to the care of their referring veterinarian by 90 days, they were followed up for survival 
status by telephone. For surviving dogs returning to us for follow-up, we aimed to collect urine 
samples for repeat measurements of u11-dTXB:Cr at each recheck appointment within the first 6 
weeks, to describe the changes in u11-dTXB:Cr  over time in these patients. All urine samples from 
recheck visits were collected by free catch either at the appointment, or within 12 hours of the 
appointment by the owners at home. Recheck appointment times were not standardised, but were 
scheduled as deemed necessary by the case clinician. As such sample timings were recorded as day 
post diagnosis, so they could later be grouped into time intervals for analysis. The planned groupings 
were; 7 days (+/-2 days), 14 days (+/- 2 days), 28 days (+/- 2 days) and 42 days (+/- 4 days) post-
diagnosis. The proportion of these samples that remained above the upper end of the u11-dTXB:Cr 
range for the normal dogs was described. Records were also assessed retrospectively for any suspicion 
of thromboembolic disease during hospitalisation, and dogs grouped into those with and without 
suspicion of thrombosis. Criteria for suspicion of thrombosis included gross thrombi or evidence of 
infarction seen on imaging or at post mortem, unexplained tachypnoea suspicious for PTE, and 
neurological signs suspicious for central nervous system (CNS) thrombosis. 
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2.3.3 PLN group 
2.3.3.1 Selection criteria 
Dogs with possible PLN were prospectively recruited. However, unlike IMHA cases which usually 
present with acute anaemia, PLN cases can have a variety of presenting complaints. This can include 
investigation of pre-identified proteinuria, hypoproteinaemia, abdominal or pleural effusions, 
subcutaneous oedema, alongside more non-specific complaints such as lethargy, hyporexia, PUPD and 
vomiting. As such it was expected that some cases would be identified at the point of admission to 
the hospital, while others may only be identified after discharge, when the results of all investigations 
became available. For cases included in this study, investigations were performed as deemed 
necessary by the case clinician to establish a diagnosis of PLN, as is standard hospital policy. 
Proteinuria was defined as a UPC > 0.5 as per current ACVIM consensus guidelines (Lees et al., 2005). 
We aimed to include only PLN cases with primary PLN, as some conditions that can underlie secondary 
PLN such as certain neoplasia and parasitic infections have themselves been associated with 
hypercoagulability and thrombotic disease (deLaforcade et al., 2019; Williams et al., 2017). Renal 
histopathology was not a requirement for study inclusion. 
2.3.3.2 Data recording and sample collection 
Standard signalment, biochemical data as was available, and final diagnosis were recorded for all 
cases. All urine samples for the study were collected by free catch, unless cystocentesis was required 
for the clinical work-up. In addition to urine being saved for thromboxane analysis, all cases had a 
routine urinalysis, urine protein-creatinine ratio (UPC) and bacterial culture as part of their clinical 
work-up for PLN, the results of which were recorded. 
2.3.4 PLE group 
2.3.4.1 Selection criteria 
Dogs with possible PLE were prospectively recruited. As with PLN, dogs with PLE can have a variety of 
presenting problems, but most commonly present with chronic diarrhoea. Other potential reasons for 
case presentation include known hypoalbuminemia, abdominal or pleural effusions or subcutaneous 
oedema (Craven and Washabau, 2019). Inclusion criteria for a diagnosis of PLE for this study were 1) 
a history of GI disease (any of weight loss, vomiting, diarrhoea, hyporexia 2) hypoalbuminemia 
(albumin <29g/l). 3) exclusion of acute GI parasitic or bacterial disease 4) exclusion of hepatic 
dysfunction. 5) absence of proteinuria. Ideally cases would also have histopathological confirmation 
of a disease process known to be associated with PLE, although this was not essential. All cases 
underwent investigation as deemed necessary by the case clinician.  
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2.3.4.2 Data recording 
Standard signalment, biochemical data as was available, and final diagnoses were recorded for all 
cases. Urine was obtained from all cases prior to any treatment with corticosteroids or other 
immunosuppressive medications. Again urine samples were collected by free catch, unless 
cystocentesis was deemed necessary as part of the clinical work-up. 
2.4 Urine sample processing and storage 
Urine samples from all dogs were frozen at -20°C within 24 hours of collection in 1ml aliquots. All urine 
was then transferred to storage at -80°C until batch analysis at a later date.  Previous studies have 
shown storage at room temperature for up to 6 days leads to no significant change in u11-dTXB 
concentrations, and it is stable long-term at -20 to -80°C (Lellouche et al., 1990; Neath et al., 2014). 
2.5 UTXB ELISA protocol 
Urinary 11-dTXB levels were measured with a commercial monoclonal ELISA kit2 previously validated 
for use in canine urine (Baltzer et al., 2006). The assay is an acetylcholinesterase (AChE) competitive 
ELISA. Briefly, this works on the basis of competition between 11-dTXB in the sample and a tracer of 
11-dTXB bound to acetylcholinesterase (11-dTXB2-AChE) for binding to a monoclonal antibody that is 
fixed to the ELISA plate. In each well the amount of tracer that can bind to the monoclonal antibody 
is inversely proportional to the amount of 11-dTXB present in the sample added. Once the plates have 
been washed, the amount of bound tracer can be determined by addition of a substrate for AChE 
(Ellmans Reagent). The metabolism of this substrate by the bound AChE causes production of a yellow 
coloured substance. The intensity of the yellow colour produced can be measured using a 
spectrophotometer, with samples with greater intensity containing proportionally more tracer and so 
less 11-dTXB from the sample. Conversely, samples with high levels of 11-dTXB outcompete the tracer 
to a greater extent, and so less yellow colour develops. The ELISAs were performed as per the 
manufacturer instructions as follows: Urine samples were defrosted to room temperature and 
centrifuged at 3000rpm for 5 minutes to remove precipitated proteins prior to dilution. The first 
samples were all run at 3 dilutions (1:2, 1:4, 1:8), however once a realistic range of the 11-dTXB level 
had been established for the IMHA dogs, subsequent samples for IMHA cases were run at 2 dilutions 
(1:5 and 1:10). Any samples with results still falling outside the linear region of the standard curve at 
 
2 Cayman chemical 11-dehydo Thromboxane B2 ELISA Kit0 Monoclonal. Item number 519510. Cayman 
Chemical, Ann Arbor, MI, USA 
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these dilutions were re-run on a subsequent plate at adjusted dilutions (1:75 and 1:150).  All sample 
dilutions for all dogs were run in duplicate. Samples were diluted with assay buffer and incubated at 
4oC overnight. The ELISA plates were set up, incubated at room temperature for 2 hours, and then 
developed as per manufacturer instructions. The plates were read using an automated plate reader3 
at 405nm wavelength after 40 to 60 minutes when the maximum tracer binding (Bo) well absorbance 
was in the range of 0.3-1.5 AU. Standard curves were calculated, and results processed using 
commercially available software4. Results from the ELISA were reported in pg/ml. The assay has a 
measurable range from 15.6-2,000 pg/ml.  Results were corrected for dilution by multiplication by the 
dilution factor, and converted to ng/ml. Where multiple dilutions gave valid results within the working 
range of the assay, these were averaged to give a final 11-dTXB concentration (ng/ml) for each urine 
sample. Any results outside the working range of the assay were discarded. The mean urine 11-dTXB 
concentration (ng/ml) was then normalised to the urine creatinine to give a urinary 11-dTXB to 
creatinine ratio (u11-dTXB:Cr). Urine creatinine was measured at a reference laboratory by the Jaffe 
reaction method and reported in umol/l (Jaffe, 1886), but was converted to mg/ml, so as to report the 
final u11-dTXB:Cr as ng/mg crea as in previous studies. 
2.6 Statistical analysis 
Data recording and statistical analysis was performed using commerically available spreadsheet 
management5 and statistics package6 software. Urinary 11-dTXB:Cr results for all disease groups, and 
IMHA subgroups were assessed for normality via visual inspection of histograms and normal Q-Q plots, 
plus Kolmogorov-Smirnov tests. Data that were normally distributed were compared between groups 
using independent-sample T tests. Non-normally distributed data were compared using Mann-
Whitney tests, and medians reported.  
For the three basic hypotheses, u11-dTXB:Cr for the dogs with IMHA, PLE and PLN was compared with 
the normal controls using either independent-sample T tests, or Mann-Whitney tests as appropriate 
based on normality testing. 
To investigate correlations between u11-dTXB:Cr and survival for IMHA, u11-dTXB:Cr at initial 
admission was also compared using Mann-Whitney tests between IMHA survival outcome groups. The 
survival outcome groups analysed were; surviors and non-survivors at hospital discharge, survivors 
 
3 LT-4500 Automatic microplate absorbance reader. Labtech, Heathfield, UK 
4 Assayzap. Biosoft, Cambridge, UK 
5 Excel, Microsoft Office 2016, Microsoft 
6 IBM SPSS Statistics for Windows, Version 24.0. Armonk, NY 
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and non-survivors at 30 days post presentation, and survivors and non-survivors at 90 days post 
presentation. To investigate correlations between u11-dTXB:Cr and disease severity for IMHA, initial 
values for parameters previously associated with either disease severity or survival (CHAOS score, 
T.bil, creatinine, urea, ALT, CRP, fibrinogen, HCT, PLT, WBC, ASA score at admission) were firstly 
compared between just the 30 day survivors and non-survivors, as descriptive analysis of the IMHA 
population. For continuous variables Mann-Whitney tests were used for analysis, for the categorical 
scores (CHOAS and ASA) Chi-squared tests were used to compare u11-dTXB:Cr between dogs with 
scores ≥3 and <3. These categories were chosen based on previous studies (Goggs et al., 2015). Where 
a stastically significant difference between the groups was identified using Mann-Whitney analysis, 
univariable binary logistic regression was used to further quantify the magnitude of effect. 
Correlations between u11-dTXB:Cr and the continous markers of disease severity for the IMHA group 
as a whole were also assessed by means of visual assesment of scatter plots, and linear regression 
analysis. Where the relationship between variables was non-linear based on visual assessment of 
scatter plots, or residuals failed the assumptions of normal distriibution and even variance based on 
histogram and pp-plot analysis, the variables were log-transformed to achieve a linear relationship. 
To evaluate u11-dTXB:Cr in dogs with thromboembolic complications of IMHA compared to those 
without, u11-dTXB:Cr at initial admission was compared between groups using Mann-Whitney tests.  
The final aim was to describe the change in u11-dTXB:Cr over the first 6 weeks of treatment. Due to 
anticipated low case numbers that would preclude statistical analysis, this part of the study was 
planned to be purely descriptive. Trends in Individual patient u11-dTXB:Cr were graphed by timepoint. 
Median and ranges for u11-dTXB:Cr at each grouped timepoint were calculated. If sufficient numbers 
were available, comparison of average u11-dTXB:Cr between each grouped timepoint and the normal 
controls would be performed, or the proportion of dogs with results above the highest control dog 





3.1 Population characteristics 
3.1.1 Healthy dog population characteristics 
Seventeen healthy dogs were volunteered, of whom one was excluded for otitis externa and 
osteoarthritic joint disease. Thus 16 ‘normals’ were included in the study. These were a range of 
breeds, of which three were Springer Spaniels. Ages ranged from 9 months to 11 years with a mean 
of 5.2 years.  
3.1.2 IMHA dog population characteristics 
Twenty-four dogs with suspected primary IMHA were recruited to the study. Two dogs were excluded, 
one because he was subsequently diagnosed with phosphofructokinase deficiency, and one because 
the IMHA was secondary to neoplasia. Two additional dogs did not have urine collected within 24h of 
admission, so were likewise excluded. Thus twenty dogs with primary IMHA were included in this study. 
There were a range of breeds, including 3 Cocker Spaniels, 2 Border Collies, 2 Springer Spaniels, 2 
crossbreeds, and one each of Labrador, Whippet, Bichon Frise, Cairn Terrier, Irish Setter, French 
Bulldog, Cockerpoo, Miniature Schnauzer, Jack Russel Terrier, Labradoodle and Pomeranian. The dogs 
ranged in age from 2 to 12 years, with a mean of 7.5 years. The mean age of the IMHA dogs (7.5 years, 
SE Mean 0.65) was not statistically significantly higher than the normal dogs (mean 5.5 years, SE Mean 
0.77) (p=0.06).  
Selected basic clinicopathological data is shown in Table 4, full data can be found in Appendix 1. Of 
note, full clotting profiles including FDP and D-dimers were only performed in 4 of twenty dogs, so 
further analysis of these data was not performed. Twelve of twenty dogs had CRP measurements 
available. Notably 11 of the 15 dogs who had fibrinogen measured had a concentration above the 




Figure 3: Box and Whisker plot of baseline fibrinogen concentrations for 15 dogs with primary IMHA. 
Red dotted lines represent laboratory upper and lower reference intervals. Box represents 75th 
percentile, median and 25th percentile. Circles represent individual data values. 
 
 
All dogs were treated with corticosteroids, with 17 starting therapy with intravenous dexamethasone, 
at a mean dose of 0.32mg/kg/day (range 0.07-0.6mg/kg/day) and three starting therapy with oral 
prednisolone, at a mean dose of 1.65mg/kg/day (range 1.01-2.0mg/kg/day). All but one dog received 
a second line immunosuppressive drug prior to discharge from hospital; twelve dogs were treated 
with mycophenolate at a mean dose of 14mg/kg/day (range 8.1-24.3mg/kg/day), six with cyclosporine 
at a mean dose of 8mg/kg/day (range 4.0-16.3mg/kg/day), two with azathioprine (dosages 2-
2.1mg/kg/day), and one dog received intravenous human immunoglobulin (0.5g/kg). Overall one dog 
was treated with a single immunosuppressive agent, seventeen dogs treated with two agents, one 
dog with three agents, and one dog with four agents. All dogs received clopidogrel for 
thromboprophylaxis, at a mean dose of 2.25mg/kg/day (range 0.97-4.7mg/kg/day). Sixteen dogs 
received one or more blood transfusions; all were given packed red cells. Exact drug combinations and 




Table 4: Selected biochemical parameters for all IMHA patients at baseline, IMHA patients surviving to 30 days post diagnosis, and IMHA 
patients not surviving to 30 days post diagnosis 
Parameter All IMHA dogs  IMHA 30 day survivors  IMHA 30 day non-survivors  P-value  
  n median range n median range n median range   
Age (years) 20 7.5 2-12 11 9 2-12 9 6 4-10 0.34 
CHAOS score points (maximum 7) 20 3.6 1-7 11 3 1-7 9 4 2-6 0.24 
T.bil (umol/l) 20 137.4 0-667 11 27 4-143 9 294 0-667 0.07 
CRP (mg/l) 12 189 41-348 6 137 40-187 6 252 121-348 0.03 
HCT (%) 20 16 10-26 11 17 12-26 9 13 10-20 0.03 
PLT (x10^12/l) 19 324 101-846 11 333 101-846 8 314 125-499 0.83 
Fibrinogen (mg/dl) 15 592 368-777 8 625 368-718 7 572 388-777 1 
Creatinine (umol/l) 20 76 35-253 11 59 37-94 9 69 35-253 0.18 
Urea (mmol/l) 19 17 5-27 10 8.3 5-112 9 15.4 7-27 0.02 
ALT (U/l) 16 325 25-2704 9 36 25-237 7 171 32-2704 0.04 
ASA score 20 3.5 2-5 11 3 2-4 9 4 3-5 0.002 
Abbreviations: IMHA, Immune mediated haemolytic anaemia; n, number; T.bil, Total bilirubin; CRP, C-reactive protein; HCT, Haematocrit; PLT, Platelet count 





3.1.3 PLN dog population characteristics 
Eight dogs with PLN were recruited to the study between April 2017 and February 2019. These 
included three Yorkshire Terriers, and one each of Lhasa Apso, Beagle, Dogue de Bordeaux, Labrador 
and Whippet. The dogs ranged in age from 9 months to 10 years, with a mean of 6.6 years. The mean 
age of the PLN dogs (6.6 years, SE Mean 1.12) was not statistically significantly different from that of 
the normal dogs (mean 5.5 years, SE Mean 0.78) (p=0.44). 
The dogs presented for a variety of reasons including hypoalbuminaemia (n=6), hypoproteinaemia 
(n=3), ascites, weight loss, azotaemia, acute blindness, CNS signs (n=2), aortic thromboembolism, and 
incidentally identified proteinuria. All dogs were proteinuric, with UPC ranging from 1.54 to 31.6, 
median UPC 10.5. For the 6 hypalbuminaemia dogs, the median serum albumin was 17.5 g/l 
(laboratory reference range 29-36 g/l), with a range of 14-25 g/l. The two normoalbuminaemic dogs 
had serum albumin levels of 30 g/l and 33 g/l respectively. Five of the 8 dogs were azotaemic at day 
0. The median creatinine for the group was 149umol/l with a range of 60-339umol/l. The median urea 
for the group was 14.9mmol/l (range 2.5-45.7mmol/l) (laboratory reference range 2.5-8.5 mmol/l). 
Basic clinicopathological data for the dogs are shown in Table 5. Two of the dogs had suspected or 
confirmed thrombi at presentation; one had presented for vestibular signs (PLN 04); one had an aortic 
thrombosis (PLN 08). One additional dog (PLN 02) developed seizures and was euthanized 4 days after 
presentation; differentials for the seizures included CNS haemorrhage due to hypertension and 
























 (ng/mg crea) 
PLN 01 5 Lhasa Fn 9.9 
ascites,  proteinuria, 
hypoalbuminaemia 
9.78 15 44 176 not suspected 0.640 
PLN 02 4 Beagle Mn 20.4 
acute azotaemia,  
proteinuria, 
hypoproteinaemia 
31.6 16 44 248 suspected 1.981 




weight loss, proteinuria, 
hypoalbuminaemia 
7.29 19 54 60 not suspected 0.953 






11.29 33 67 122 suspected 1.157 






1.54 30 76 114 not suspected 0.567 






20.5 19 59 339 not suspected 1.548 
PLN 07 8 Labrador Me 28.6 
skin disease,  
proteinuria, 
hypoalbuminaemia 
3.9 25 72 60 not suspected 1.854 
PLN 08 8 Whippet Fn 16.4 
hindlimb weakness, 
proteinuria 
11.23 14 39 194 aortic thrombus 0.358 
Abbreviations: PLN, Protein-losing nephropathy; UPC, urine protein-creatinine ratio; Fn, female neutered; Mn, male neutered; Me, male entire; Fe female entire 
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3.1.4 PLE dog population characteristics 
Seven dogs with PLE were recruited to the study between August 2017 and November 2018. This 
included two Border Collies, and one each of a Staffordshire Bull Terrier, Soft Coated Wheaten Terrier, 
Springer Spaniel, German Short Haired Pointer, and Cocker spaniel. All dogs presented for a history of 
chronic diarrhoea, most already had hypoalbuminaemia identified by their referring vets. The dogs 
ranged in age from 4 years to 11 years, with a mean of 8.6 years. The mean age of the PLE dogs (8.6 
years, SE Mean 0.90) was statistically significantly higher than the normal dogs (mean 5.5 years, SE 
Mean 0.78) (p=0.02). 
All dogs were hypoalbuminaemic; the median serum albumin was 18g/l (laboratory reference range 
29-36g/l) with a range of 14-22 g/l. Folate and cobalamin (B12) levels were measured at presentation 
in 6 of the 7 dogs. Of those, folate was normal in 3 dogs, and increased in 3. Cobalamin was below the 
lower end of the laboratory reference range (200ng/l) in one dog, with a median concentration for 
the group of 158ng/l, range 168 – 1807 ng/l. Basic clinicopathological data for the group is shown in 
Table 6.  Only one dog had a suspicion of thromboembolic disease; she had been having unexplained 
neurological episodes over the preceding month and had evidence of old renal infarcts on abdominal 
ultrasound.   
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18 34 3.3 168 not suspected 0.621 
PLE 02 9 





14 29 3.9 372 not suspected 0.955 






22 53 15 986 not suspected 1.650 
PLE 04 4 





17 35 >20 1807 not suspected 0.771 
PLE 05 9 Cocker spaniel Fn 9.8 
Chronic diarrhoea, 
hypoalbuminaemia 
20 44 >20 485 not suspected 2.189 
PLE 06 11 Border collie Fn 17.8 
Chronic diarrhoea, 
hypoalbuminaemia 
14 30     not suspected 1.376 
PLE 07 11 Border collie Fn 15.5 
Chronic diarrhoea, 
hypoalbuminaemia 
18 34 3 552 suspected  0.478 





3.2 Urine thromboxane results 
3.2.1 ELISA performance data 
Nine ELISA plates were used to obtain the u11-dTXB results within this study. Intra-plate assay 
performance data for the nine individual plates is shown in Table 7. Inter-plate performance was not 
assessed as part of this study, but has ranged from 12- 20% in previous published studies measuring 
u11-dTXB (Baltzer et al., 2006). 
 
Table 7: Intra-plate performance data for the nine individual 
ELISA plates used to measure u11-dTXB 
Plate mean CV maximum CV 
1 5.6 16.6 
2 4.1 15.9 
3 7.7 23 
4 3.5 11.3 
5 6.6 17.7 
6 3.8 10.2 
7 7.6 23.4 
8 7.6 10.1 
9 6.7 12.9 
Abbreviations: CV, coefficient of variation 
 
 
3.2.2 Healthy controls 
The 16 normal dogs had u11-dTXB:Cr results ranging from 0.24 to 2.57 ng/mg crea. These values were 
not normally distributed (Figure 4).  One result was an extreme outlier, so was removed from further 
analysis (u11-dTXB:Cr 2.57ng/mg crea). The median u11-dTXB:Cr for the remaining 15 normal dogs 
was  0.62 ng/mg crea (SD 0.28, range 0.24-1.32).  
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Figure 4: Box and whisker plot of u11-dTXB:Cr for 16 healthy control dogs. Box represents 





3.2.3 IMHA results 
3.2.3.1 IMHA whole group baseline thromboxanes 
The 20 IMHA dogs had u11-dTXB:Cr results ranging from 0.83- 25.36 ng/mg crea. These values were 
not normally distributed. The median baseline u11-dTXB:Cr for the IMHA dogs was 3.76 ng/mg crea 
(SD 5.34). This was significantly higher than for the normal dogs (median 0.62, SD 0.56, range 0.24-
1.32)(p<0.001) (Figure 5). A post-hoc power calculation using a freely available online tool7 showed β= 
0.94 for this comparison. Thirteen of twenty IMHA dogs had baseline u11-dTXB:Cr higher than the 
upper end of the range for the normal dogs (1.32 ng/mg crea). Individual results for all IMHA dogs at 
baseline are shown in Appendix 1. 
 
Figure 5: Box and whisker plots of baseline u11-dTXB:Cr for dogs with IMHA, PLN and PLE 
compared to healthy controls. Boxes represent 75th percentile, median and 25th percentile. 








3.2.3.2 IMHA dog baseline subgroup analyses 
3.2.3.2.1 Survival outcome subgroups 
Of the 20 IMHA dogs, 11 (55%) survived to discharge, giving an in-hospital mortality rate of 45%. Of 
the non-survivors, 5 died naturally while 4 were euthanised. Of the 4 euthanised, two were euthanised 
at days 1 and 2 of treatment due to development of neurological signs attributed to thromboembolic 
disease, while the other two were euthanised after 5 and 10 days of treatment due to ongoing 
transfusion requirements.  Of those surviving to discharge, hospitalisation time was a median of 8 days 
(range 3-14 days). Two dogs relapsed within 90 days of discharge, one at day 57 post diagnosis and 
one at day 67 post-diagnosis, both of whom died. This gave a 30-day survival rate the same as the 
survival to discharge rate, of 55%, and a 90-day survival rate of 45% (Figure 6). 
 
Figure 6: Kaplan Mayer survival curve for 20 dogs with primary IMHA for the first 120 days 






There was no significant difference in u11-dTXB:Cr at presentation between dogs with IMHA surviving 
to 30 days post diagnosis (median 2.20 ±7.2 , range 0.83-25.36)) and those dying within 30 days of 
diagnosis (median 4.29 ±1.6, range 1.71-6.28)(p=0.45)(Figure 7). Identical results were found for dogs 
surviving and not surviving to discharge. There was also no significant difference in u11-dTXB:Cr at 
presentation between IMHA dogs surviving to 90d (median 1.57 ±3.0, range 0.83-8.37) and those not 
(median 4.29 ±6.6, range 1.71-25.36)(p=0.22)(Figure 8). Post-hoc power calculations, however, 
showed these comparisons were underpowered, with β=0.08 for the 30d groups, and β=0.18 for the 
90d groups.  
 
Figure 7: Box and whisker plots of u11-dTXB:Cr for surviving and non-surviving dogs at 30 
days post diagnosis with primary IMHA. Boxes represent 75th percentile, median, and 25th 





Figure 8: Box and whisker plots of u11-dTXB:Cr for surviving and non-surviving dogs at 90 days 
post diagnosis with primary IMHA. Boxes represent 75th percentile, median, and 25th 
percentile. Asterisks represent outliers.  
 
 
3.2.3.2.2 Disease activity outcomes 
Of the variables previously identified as markers of disease severity in IMHA, the median CRP, urea, 
ALT and ASA score were all significantly higher at presentation in dogs that died within 30d of diagnosis 
than those surviving to 30d. Additionally HCT was significantly lower in 30d non-survivors than in 
survivors (Table 4 and Figure 9). To further investigate these relationships, binary logistic regression 
was performed for survival status at 30d and CRP, urea, ALT, and HCT. Of these, only urea retained 
statistical significance, with an increase of 1mmol/l urea having an odds ratio of 1.36 for non-survival 
at 30d (95% CI 1.002-1.860, p=0.049) (Table 7). As only 12 cases had data for CRP, and 16 for ALT, 
insufficient case numbers were available for multivariable binary logistic regression, so this was not 
performed. The proportion of dogs with CHAOS score <3 and ≥3 was also compared between 30d 
survivors and non-survivors using a chi-squared test. Of the 5 dogs with CHAOS score <3, four (80%) 
were alive at 30d, while of the 15 with CHAOS score ≥3, seven (47%) were alive at 30d. This difference 
was not statistically significant (p=0.19). 
u11-dTXB:Cr was assessed for correlation with the known markers of inflammation and disease 
severity (CRP, HCT, PLT, CHAOS score, T.bil, Crea, Urea, ALT, WBC, fibrinogen and ASA score) plus age 
in the 20 dogs with IMHA using linear regression analysis. For all analysis log-transformation of u11-
dTXB:Cr was required for the model’s assumptions to be valid.  No statistically significant correlations 








Table 8: Binary logistic regression analysis for selected baseline parameters with survival 
status at 30 days post diagnosis for dogs with IMHA 
Parameter n (total) Exp(β) 
95% CI for Exp(β) 
p-value 
lower upper 
HCT 20 0.749 0.552 1.016 0.063 
CRP 12 0.067 0.998 1.068 0.067 
Urea 19 1.365 1.002 1.86 0.049* 
ALT 16 1.01 0.994 1.027 0.233 
Abbreviations: CI, Confidence interval; CRP, C-reactive protein. 
Notes: Exp(β) is the test statistic. * denotes statistical significance 
 
Figure 9: Box and Whisker plots of baseline CRP (n = 12) , Urea (n = 19), ALT (n = 16) and 
HCT (n = 20) for surviving and non-surviving dogs at 30 days post diagnosis with primary 





Table 9: Results from linear regression analysis for selected markers of disease severity 
and urinary thromboxanes in dogs with IMHA 
Parameter n (total) R2 β 
95% CI for β 
p-value 
lower upper 
Age 20 0.001 -0.01 -0.16 0.14 0.886 
CRP 12 0.09 -0.01 -0.009 0.007 0.767 
HCT 20 0.011 -0.022 -0.122 0.079 0.658 
log(PLT) 19 0 0.021 -0.71 0.752 0.952 
log(T.bil) 20 0.012 -0.23 -0.3 0.3 0.867 
Creatinine 20 0.001 0 -0.007 0.008 0.898 
Urea 19 0.005 0.11 -0.064 0.085 0.076 
log(ALT) 16 0.01 0 -0.001 0.001 0.707 
WBC 19 0.022 -0.13 -0.55 0.3 0.54 
Fibrinogen 15 0.07 -0.002 -0.006 0.002 0.34 
Abbreviations: CRP, C-reactive protein; HCT, haematocrit; PLT, platelet count; T.bil, total bilirubin; WBC, 
total white blood cell count. 
Notes: All parameters were assessed against log(u11-dTXB:Cr) to achieve a linear relationship for model 





3.2.3.2.3 Thrombosis outcome subgroups 
Five of the 20 IMHA dogs had a suspicion of thromboembolic disease during hospitalisation. One dog 
suffered a sudden respiratory arrest suspected to be a result of PTE, two developed neurological signs 
including nystagmus and seizures, and two dogs developed a combination of unexplained tachypnoea 
and neurological signs. Of these dogs, 4 died or were euthanised at the time of the suspected 
thrombotic event, while one survived to discharge. There was no significant difference between the 
median u11-dTXB:Cr of these 5 dogs (4.29 ± 1.75, range 2.2-6.3) and the rest of the IMHA group (3.48 
± 6.14, range 0.83-25.4)(p=0.6) (Figure 10). However a post-hoc power calculation gave a β of only 
0.07 for these group sizes.   
Figure 10: Box and whisker plots of u11-dTXB:Cr for dogs with primary IMHA with and 
without a suspicion of thromboembolic disease during hospitalisation. Boxes represent 75th 
percentile, median and 25th percentile. Asterisks represent outliers. 
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3.2.3.3 Serial measures in surviving IMHA dogs 
Of the 11 dogs surviving to discharge, repeat urine samples were obtained at at-least one follow-up 
timepoint for 9 of them. Exact-day results for individual dogs are shown in Figure 11. Due to more 
variability than had been anticipated in the actual ‘day number’ for follow-up visits, the original 
planned groupings were altered from ‘7 days (+/-2 days), 14 days (+/- 2 days), 28 days (+/- 2 days) and 
42 days (+/- 4 days) post-diagnosis’ to three new broader categories, each covering consecutive two-
week periods of ‘2-15 days, 16-29 days and 30 to 42 days’. Eight samples from 7 dogs were available 
in days 2 to 15 post-diagnosis, eleven samples from 8 dogs in days 16 to 29, and three samples from 
2 dogs in days 30 to 42. For the day 2 to 15 interval, no samples were collected sooner than day 6. The 
median and range for IMHA dogs at each grouped time-point is shown in Figure 12 and Table 9. The 
median u11-dTXB:Cr for the IMHA dogs was at all time points was statistically higher than that of the 
normal dogs. The proportion of samples at each time point with u11-dTXB:Cr levels above the upper 




















































 (ng/mg crea) 
Range u11-
dTXB:Cr  




controls day 0 15 15 0.62 0.24 1.32 n/a n/a 
IMHA day 0 20 20 3.76 0.83 25.4 <0.001* 17/20 
day 2 - 15 8 7 3.02 0.53 15.4 0.001* 7/8 
day 16 - 29 11 8 3.35 0.41 7.76 <0.001* 8/11 
day 30 - 42 3 2 1.88 1.25 2.51 0.011* 2/3 
Notes: p-values are for comparison with baseline control group median u11-dTXB:Cr. * denotes statistical 
significance. High results are as compared to the highest control dog u11-dTXB:Cr value (1.32 ng/mg crea) 
 
Figure 12: Box and whisker plots of u11-dTXB:Cr for surviving dogs with primary IMHA at 
serial timepoints post-diagnosis. Boxes represent 75th percentile, median, and 25th 
percentiles. Asterisks represent outliers. Red dotted line represents upper range value of 
u11-dTXB:Cr for the control dog group 
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3.2.4 PLN results 
The 8 dogs with PLN had u11-dTXB:Cr results ranging from 0.36 to 1.98 ng/mg crea. These values were 
not normally distributed. The median u11-dTXB:Cr was 1.06 ng/mg crea (SD 0.61), which was not 
significantly different from the median for the normal dogs (median 0.62 ng/mg crea (SD 0.28, range 
0.24-1.32)(p=0.065) (Figure 13, and Figure 5 in comparison to IMHA). A post-hoc power calculation for 
this data gave β=0.64.  
3.2.5 PLE results 
The 7 dogs with PLE had u11-dTXB:Cr results ranging from 0.48 to 2.19 ng/mg crea. These values were 
not normally distributed. The median u11-dTXB:Cr was 0.96 ng/mg crea (SD 0.62), which was 
significantly higher than the median for the normal dogs (median 0.62 ng/mg crea (SD 0.28, range 
0.24-1.32)(p=0.026) (Figure 13, and Figure 5 in comparison to IMHA). A post-hoc power calculation for 
this data gave β=0.60 
 
  
Figure 13: Box and whisker plots of u11-dTXB:Cr for dogs with PLN and PLE, compared to 
control dogs. Boxes represent 75th percentile, median and 25th percentiles. Asterisks 





This study had three main goals; to assess whether u11-dTXB:Cr is increased in dogs with PLN, PLE, 
and IMHA compared to normal dogs, to look at whether u11-dTXB:Cr correlates with disease severity, 
outcome, or incidence of thrombosis in IMHA, and to describe the change in u11-dTXB:Cr over the 
first weeks of treatment in dogs with IMHA. This discussion will first focus on the baseline measures 
of u11-dTXB:Cr in dogs with the three conditions, before returning to discuss the serial measures in 
the IMHA dogs at the end.  
4.1 Baseline urinary thromboxanes 
Firstly, this study has shown that u11-dTXB:Cr is significantly higher at presentation in dogs with both 
IMHA and PLE than in normal dogs. It was not, however, statistically different between dogs with PLN 
and normal controls. This may suggest that increased platelet activation is important in the 
pathogenesis of the prothrombotic state seen in IMHA and PLE, but not in PLN. In human medicine, 
u11-dTXB:Cr is a well-established marker of in vivo platelet activation. It has been found to be 
increased in multiple prothrombotic conditions including stroke, myocardial infarction and 
atherosclerosis (Foegh et al., 1994)(McConnell et al., 2001)(Eikelboom et al., 2002)(Wang et al., 2018). 
There are multiple sources of thromboxane within the body, including platelets, vascular endothelial 
cells, and inflammatory cells such as monocytes (Fontana et al., 2014). As such thromboxane 
production can be increased in many situations, including activation of platelets, vascular endothelial 
damage or inflammation, and generalised inflammatory states. Numerous studies have shown that 
thromboxane is a potent activator of platelets, in dogs and people, and so irrespective of the source, 
increased serum thromboxane levels will lead to increased platelet activation. Additionally, platelet 
activation is a key step at the point of thrombus formation, irrespective of the driving factors that have 
led to that point. Thus increased u11-dTXB:Cr may be considered to represent evidence of increased 
platelet activation, and so potentially a prothrombotic state, in dogs with IMHA and PLE. 
Equally, while the group median u11-dTXB:Cr was not increased in the dogs with PLN, there was 
significant overlap between the range of u11-dTXB:Cr with the control dogs. This overlap with the 
normal dogs was also present for both the IMHA and PLE group ranges as well.  Given that thrombosis 
does not occur in all individual dogs with these diseases, and so presumably not all individuals will be 
prothrombotic, it is unsurprising that there is this overlap. To answer the question of whether u11-
dTXB:Cr truly is a useful biomarker of thrombotic risk, future studies would need to identify a 
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reference range for the level in normal patients, and look for any difference in the incidence of 
thrombosis in groups of patients with increased u11-dTXB:Cr, compared to those with the same 
disease and normal levels. At this stage, however, the overlapping ranges of u11-dTXB:Cr seen 
between the diseased and healthy individuals may suggest that either not all diseased individuals are 
equally prothrombotic, or that different individuals with the same disease have differing degrees of 
platelet activation. 
The below sections explore the specific relevance of the u11-dTXB:Cr findings further in the individual 
disease states, before looking into some of the general limitations of this study. 
4.1.1 IMHA  
More specifically for the dogs with IMHA, the theory that this finding of increased baseline u11-
dTXB:Cr represents increased platelet activation is consistent with previous studies showing increased 
platelet activation in these patients. Increased platelet activation has been demonstrated directly via 
increased platelet P-selectin expression on flow cytometry, increased platelet microparticle levels, and 
lower mean MPC concentrations in patients with IMHA. There is also evidence of increased 
intravascular TF expression and high levels of circulating Neutrophil extracellular traps (NETs), both of 
which are prothrombotic, and can lead to platelet activation in vitro. Given that IMHA is an acute, 
highly inflammatory disease, it is possible that the measured u11-dTXB:Cr is not solely of platelet 
origin, but also from endothelial cells due to vasculitis, and from inflammatory leucocytes themselves.  
While the mechanism of the increased u11-dTXB:Cr in the IMHA dogs was not specifically investigated 
in the present study, any correlations with known markers of disease severity, markers of 
inflammation such as WBC and CRP, and with platelet count were assessed. No correlations between 
any of these variables and u11-dTXB:Cr were found. As such it could be argued that difference in u11-
dTXB:Cr between individual dogs with IMHA is not simply reflective of the severity of their IMHA, the 
severity of the associated inflammation, nor simply a reflector of platelet number. This implies that 
u11-dTXB:Cr is a measure of an aspect of the pathophysiology in these IMHA patients that cannot 
currently be accurately assess, and adds weight to the theory that it may be a marker of platelet 
activation, and so thrombotic risk. In human, as in veterinary medicine, there is an ongoing need for a 
predictor of thrombosis in patients with autoimmune haemolytic anaemia. Epidemiologic studies have 
identified a link between active haemolysis and the risk of thrombosis, since VTE occur predominantly 
during acute flare ups of disease (Audia et al., 2018; Lecouffe-Desprets et al., 2015). Patients with 
jaundice, and higher white cell counts are also more likely to suffer VTE (Audia et al., 2018). This is 
similar to the association between jaundice and thrombosis identified in previous studies in dogs (Carr 
et al., 2002). To date, however, there are still no biomarkers identified with utility in predicting 
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thrombosis in either the veterinary or human fields.  Researchers have investigated free haemoglobin, 
NO metabolites, and soluble CD163, a marker of macrophage activation, but have not identified 
differences in these between patients with and without VTE (Audia et al., 2018). To the authors 
knowledge, thromboxane levels have not been investigated in human patients with AIHA.  
4.1.1.1 Association with Survival 
This study additionally evaluated, but found no difference between, u11-dTXB:Cr levels in dogs 
surviving and not surviving to 30 days and 90 days post presentation.  The association between u11-
dTXB:Cr and survival was chosen for two reasons. Firstly, thrombosis is reported to be a major cause 
of mortality in IMHA patients but can be very difficult to detect clinically. As such it seemed likely that 
there would be an association between non-survival and thrombosis, but with non-survival being 
easier to document than thrombosis. Thus it was hypothesised that if there were an association 
between u11-dTXB:Cr and thrombosis, there may also be an association between u11-dTXB:Cr and 
non-survival. The second reason was that currently, while CHAOS score ≥3 has been associated with 
an increased risk of death, survival outcome in dogs with IMHA still cannot be predicted from data 
available at clinical presentation. As such, evaluation of the utility of u11-dTXB:Cr as a general 
predictor of outcome was felt to be worthwhile, irrespective of any association with thrombosis.  
There are multiple possible reasons why this study may not have identified an association between 
u11-dTXB:Cr and survival outcome. Firstly, there are multiple different reasons why dogs with IMHA 
may not survive. These encompass patient factors such as disease severity, treatment factors such as 
choice of immunosuppressant or availability of blood transfusion and owner factors such as 
willingness or financial ability to pursue treatment. While many canine IMHA patients expire naturally, 
from cardiac or respiratory failure, as with all veterinary studies assessing survival the option of 
euthanasia is a significant confounding factor. Some patients will be euthanised due to their 
deteriorating condition alone, however in most the reasons for euthanasia are more complex, 
involving owner ethical and financial considerations alongside the clinical state and predicted 
prognosis for the individual patient. Of the 9 non-survivors in this study, 4 were euthanized, of which 
two had developed severe neurological signs and euthanasia was considered inevitable. The other 
two, however, were euthanised due to the need for repeated blood transfusion after 11 and 6 days of 
therapy respectively, and the possibility that they would have survived with a yet longer duration of 
treatment cannot be excluded. Equally, for those dogs that died naturally, thrombosis is not the only 
potential cause of death. Of the 5 patients that died, a thrombus (PTE) was suspected in two and 
cannot be excluded in a third, however the remaining two patients had both developed renal failure 
and acidosis at the time of death, with no overt suspicion of thrombosis. Equally, in human medicine, 
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while historically, VTE was reported to be the major cause of death in patients with AIHA, a more 
recent study found the risk of death did not differ between patients that did and did not suffer from 
thrombosis during their treatment. The authors speculated that this was due to improvement in the 
management of patients with VTE, that meant that some patients with VTE were now surviving with 
treatment (Audia et al., 2018). Equally in dogs, while thrombosis was seen in 80% of patients in post-
mortem studies, a previous study assessing for evidence of PTE in IMHA dogs found no correlation 
between CT angiogram findings consistent with PTE and outcome, with two dogs with confirmed PTE 
and two with suspected PTE surviving (R. Goggs et al., 2014).  While large thrombi that cause 
impairment of end-organ function may lead to death, particularly in the case of PTE, smaller thrombi 
may not, and in some cases can be subclinical entirely. As such, while an initial hypothesis was that 
u11-dTXB:Cr may be associated with survival, one of the reasons it was not may be that there is only 
limited association between thrombosis itself and survival. As such this finding does not exclude the 
possibility that u11-dTXB:Cr may be clinically useful in other ways, in particular for investigating 
platelet activation. 
 It is also possible that u11-dTXB:Cr was not associated with survival in this population of dogs because 
of type II error from the small survivor and non-survivor group sizes. As assessing for an association 
with survival was a secondary aim of the study, a-priori power analysis was not performed for this 
comparison. Post-hoc power analysis for both the 30 day and 90 day groups, however,  showed that 
these comparisons were significantly underpowered. In addition, this population may not be truly 
representative of the larger population of dogs with IMHA. This study was performed in a tertiary 
referral hospital, and on the whole only the sicker end of the severity spectrum of patients present to 
the hospital for care. As such, to evaluate whether this population is in line with other larger 
populations of dogs with IMHA reported in the literature, known markers of disease severity were 
evaluated for correlation with outcome. As in previous studies, baseline CRP, urea, ALT and ASA score 
were all significantly higher in 30-day non-survivors, with HCT also being significantly lower. Unlike in 
previous studies, however, there was no significant difference in total white cell count, bilirubin, or 
CHAOS score. Again, It is possible this is in part due to type II error from the small group sizes once the 
cases are divided into survivors and non-survivors. Equally, although not statistically significant, the 
proportion of dogs surviving with CHAOS score <3 surviving was substantially higher than that of those 
with score >3 (80% vs 47%), raising the possibility the result was statistically non-significant mainly 
due to type II error. Overall, these findings suggest the IMHA population in this present study is similar 
to that reported in the literature previously, although again most of the literature regarding IMHA in 
dogs has come from similar referral centres. Thus it cannot be excluded that there may be a difference 
in u11-dTXB:Cr between this population and dogs more mildly affected with IMHA. Equally, as most 
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dogs in this study had increased CRP, fibrinogen, and white cell counts, consistent with inflammation, 
it is possible no association was found between u11-dTXB:Cr and these parameters because the 
population did not include any more mildly affected dogs with IMHA, with lower values.  
Additional reasons that could contribute to there being no significant difference in u11-dTXB:Cr 
between survivors and non-survivors include the effect of differences in treatments on outcome. 
Standard treatment for dogs with IMHA includes the use of immunosuppressive and anti-thrombotic 
therapy, however there are several different individual drugs within these categories commonly used 
in the referral hospital (Goggs et al., 2019; Swann et al., 2019). All therapeutic decisions were made 
by case clinicians, as is normal hospital policy, with no attempt to standardise therapy. Thus dogs had 
a wide range of immunosuppressive strategies, with varying drug combinations and dosages. This 
study was not designed to assess the impact of therapeutics on outcome, and so no comparisons of 
survival between different regimens was attempted, however it is possible that some dogs received 
treatment regimens that were more effective than others. In particular clinicians will often start dogs 
perceived as being sicker on multiple immunosuppressives from the outset, rather than starting with 
a single immunosuppressive. Whether this improves the efficacy of treatment is currently unknown. 
However differences in treatment such as this may have been a confounding influence on any 
relationship between baseline u11-dTXB:Cr and survival. As such it would be interesting to further 
evaluate u11-dTXB:Cr in any future prospective studies assessing the impact of standardised 
treatments on outcome. 
Finally, it is possible that other factors differing between the dogs at baseline had an impact on the 
u11-dTXB:Cr levels, and masked any association with survival. There was no significant difference in 
age between the IMHA survival subgroups, nor was there a correlation between age and u11-dTXB:Cr 
on regression analysis, to suggest that age has a significant impact on u11-dTXB:Cr levels. Associations 
between u11-dTXB:Cr and breed were not evaluated given the small samples sizes within this study. 
Several breed-specific differences in haematological and biological parameters are well-known in 
veterinary medicine, particularly in sighthound breeds, so it is possible that u11-dTXB:Cr may also 
show some breed-associated variability, and this accounts for the differences in this IMHA population 
(Zaldívar-López et al., 2011). In addition, most IMHA dogs were already receiving at least one 
medication at the time of inclusion in this study. It was an inclusion requirement that all dogs were 
not already receiving anti-thrombotic therapy at the time the urine sample for u11-dTXB:Cr was 
collected, however for practical reasons patients were only excluded if they had been receiving 
corticosteroids for over 48h, similar to other veterinary studies of IMHA. However the majority of dogs 
had received one or more dosages of steroid at the time of inclusion. There is evidence in both human 
and veterinary medicine, that corticosteroids cause changes to some haemostatic parameters, and 
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may be prothrombotic (deLaforcade et al., 2019; van Zaane et al., 2010).  A recent consensus 
statement on populations at risk for thrombotic disease in dogs and cats thus came to two conclusions 
regarding glucocorticoids in dogs. Firstly that corticosteroid administration favours a hypercoagulable 
state in dogs. And secondly that treatment with corticosteroids may be associated with the 
development of thrombosis in dogs, in particular those with other risk factors for thrombosis 
(deLaforcade et al., 2019). In a study evaluating the effects of various immunosuppressives on u11-
dTXB:Cr in 8 healthy dogs, prednisolone was found to increase u11-dTXB:Cr in some, but not all of 
them (Thomason et al., 2018). Overall the impact of prednisolone was very inconsistent, but it does 
raise the possibility that prior glucocorticoid treatment had an impact on u11-dTXB:Cr levels in dogs 
in this present study. This may have both impacted on the magnitude of difference between IMHA 
dogs and normal dogs, and also been a confounding factor on any association between u11-dTXB:Cr 
and survival outcome.  
4.1.1.2 Association with Thrombosis 
Baseline u11-dTXB:Cr also did not differ between dogs that did and did not go on to have suspected 
thrombotic complications. This may suggest that u11-dTXB:Cr is not useful as a marker of thrombotic 
risk, but may also be due to this comparison being underpowered, as shown by a post-hoc calculation 
giving the power as only 6.5%. There were also a number of significant limitations around the 
detection of thrombosis in this study. As outlined in the introduction, detection of thrombi is difficult 
in both human and veterinary patients. In none of the five patients with a suspicion of thrombosis was 
the diagnosis confirmed; they were all classified on consistent clinical signs alone. None of the dogs 
suspected of having CNS thrombosis had confirmatory MRI, nor did those with suspected PTE have CT 
angiography, as all but one were euthanised or died at the time of suspect thrombosis. Equally, 
consent for post-mortem was not given for any of the non-surviving patients, either with or without a 
suspicion of a thrombus at the time of death. This means not only was the clinical suspicion not 
confirmed in any patient, but that subclinical thrombosis in those who died also cannot be excluded. 
As there was also limited ongoing screening for thrombosis in the surviving patients, subclinical 
thrombosis in that population is equally possible. Ideally repeat thoracic and abdominal imaging would 
have been performed both at fixed serial time-points over the course of treatment, and at any time 
thrombosis was suspected, however this was not justifiable clinically. It was initially intended to 
measure FDPs and D-dimers at the time of presentation to look for correlations between the 
parameters and u11-dTXB:Cr. However clinicians only requested FDPs and D-dimers as part of their 
clinical work-up in 4 of the 20 included cases, and in no cases was surplus blood collected into sodium 
citrate tubes for later analysis as per the study request guidelines. As such it was not possible to look 
for correlations between FDPs, D-dimers and u11-dTXB:Cr. Overall the likely most significant factor 
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that may have impacted on these results is inaccurate classification of dogs into the thrombus status 
groups. Further studies with a focus on better detecting thrombi, plus additional measures of 
hypercoagulability such as TEG would be useful to better establish how u11-dTXB:Cr levels correlate 
with clinical risk of thrombosis to individual patients. 
Aside from these limitations regarding detecting thrombi, there may be other causes for the lack of 
an association between u11-dTXB:Cr and thrombosis. Firstly it is possible that u11-dTXB:Cr does 
reflect increased platelet activation, but the physiological relationship between platelet activation and 
subsequent thrombus formation is not straightforward, with other factors such as blood stasis or 
hypercoagulability playing a more significant role in whether a thrombus actually forms in dogs with 
IMHA. Secondly, although there is a large body of research showing that thromboxane A2 causes 
activation of platelets, in one early study looking specifically at canine platelet function it was found 
that only 30% of dogs have platelets sensitive to arachidonate, the precursor of thromboxane 
(Johnson et al., 1979). Further research suggested that responsiveness to thromboxane is inherited as 
an autosomal recessive trait in dogs (Johnson et al., 1991). As such, it can be speculated that u11-
dTXB:Cr might be a marker of thrombotic risk only in that 30% of dogs with platelets sensitive to its 
effect. In those dogs without platelets sensitive to thromboxane, there may be very little relationship 
between thromboxane levels and the level of platelet activation, and so also no relationship between 
u11-dTXB:Cr and the occurrence of thrombosis.  Equally, although activated platelets do themselves 
produce thromboxane, irrespective of what the activating signal is, u11-dTXB:Cr is also derived from 
other sources of thromboxane such as inflammatory cells and endothelial cells. While in healthy dogs, 
a number of studies have shown changes in u11-dTXB:Cr associated with alterations in platelet 
function, it is unknown whether platelets are the main source of thromboxane production in dogs with 
diseases such as IMHA (Dudley et al., 2013; Thomason et al., 2016, 2018). In people, under normal 
physiological conditions, between 70 and 80% of serum thromboxane is produced by platelets, with 
monocytes being the main extra-platelet source (Lellouche et al., 1990). However the proportion of 
thromboxane produced by monocytes has been shown to be increased in various inflammatory states, 
in particular by inflammation associated with atherosclerotic plaques (Wang et al., 2018). Whether 
the similar situation occurs in dogs is unknown, but would be physiologically plausible. As such, 
changes in u11-dTXB:Cr in dogs with disease may not always result from, or lead to, changes in platelet 
activation. 
This study also did not evaluate the relationship between u11-dTXB:Cr and the time at which a 
thrombus was suspected. It is known that D-dimer levels show very acute changes at the time 
thrombosis occurs. In one study of D-dimer pharmacokinetics, there was a sharp peak in their 
concentration in the first two hours after PTE occurrence, with levels declining back to baseline within 
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24 hours (Ben et al., 2007). There may be a similar chronological association between u11-dTXB:Cr 
and thrombosis, with u11-dTXB:Cr levels increasing only very shortly before thrombi occur, as mass 
platelet activation begins. This study was designed with the primary aim of evaluating whether u11-
dTXB:Cr was increased in dogs with IMHA, with evaluating for any association with thrombosis as a 
secondary aim. As such u11-dTXB:Cr was not serially evaluated more often than every 7-14 days, so 
any acute changes in u11-dTXB:Cr could have been missed in those patients with suspected thrombi.  
Finally, as with evaluating for an association with survival, it is possible that differences in anti-
thrombotic therapy between the dogs was a confounding factor on any relationship between their 
initial u11-dTXB:Cr and whether they subsequently developed thrombi. While all clinicians chose 
clopidogrel as antithrombotic therapy in the IMHA dogs, a range of different dosages were used, likely 
largely dictated by tablet size available. This may have variably impacted on the subsequent risk of 
thrombosis in individual patients, and confounded any relationship with baseline u11-dTXB:Cr. 
Overall the finding that u11-dTXB:Cr did not differ in dogs with and without suspected thrombi in this 
study may indicate it will not be a useful future biomarker of thrombotic risk in dogs with IMHA. 
However there were a number of limitations to this present study that mean further evaluation of 
u11-dTXB:Cr alongside additional markers of platelet activation, and with more thorough evaluation 
for the presence or absence of thrombosis would be required to better evaluate its utility.  
4.1.2 PLN 
In this study, there was no significant difference in the u11-dTXB:Cr in dogs with PLN compared to the 
controls. The difference in the medians was similar, however, to that of the PLE dogs, and did approach 
significance, with a p-value of 0.07. Post-hoc power analysis showed this comparison to be 
underpowered to detect a statistically significant difference between the groups, with a power of only 
64%. As such it is possible that the small case numbers have led to a type 2 error, and inclusion of a 
larger number of dogs would have revealed a significant difference. In particular, given the range of 
u11-dTXB:Cr seen in the PLN dogs is wider than that of the normal controls to a similar degree as that 
of the PLE dogs, it seems likely that there is significant individual animal variation in thromboxane 
levels. Unfortunately, despite the study covering a two-year period, fewer dogs with PLN were 
recruited to the study than was anticipated. In part this was due to a diagnosis of PLN often being 
reached from test results received after patients had already left the hospital, so that fresh urine 
samples were not available for inclusion into the study.  
It is also possible no difference in u11-dTXB:Cr between the groups was found because the 
pathogenesis of thrombosis in PLN is different to that in PLE and IMHA, and platelet activation does 
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not play as significant a role in the mechanisms of thrombotic risk, or only occurs later in the risk 
period when active clot formation has started. In the human field, the main abnormalities thought to 
contribute to thrombosis in nephrotic syndrome are to do with alterations to the coagulation system, 
including loss of anti-coagulant molecules in the urine. However evidence of increased platelet 
activation has also been found in numerous studies. It has additionally been shown that u11-dTXB:Cr 
levels are higher in people with new-onset or relapsing nephrotic syndrome compared to healthy 
controls. Taken together this suggests that a type 2 error may be likely in this present study, and 
including a larger number of PLN dogs may have found a significant difference. So far in dogs, there 
has been very little work done looking at the role of platelet activation in the prothrombotic state 
associated with PLN. The majority of research has focused either on the contribution of anti-thrombin, 
or on measures of hypercoaguability. As such very little is known about whether platelet activation 
may be similarly increased in dogs with PLN as it Is in people with nephrotic syndrome. Work in dogs 
with uraemia due to CKD has, however, identified evidence of platelet activation, in the form of 
increased surface expression of GPIb, αIIbβ3, and P-selectin (Dudley et al., 2017). As such further 
evaluation of u11-dTXB:Cr in a larger population of dogs with PLN, including differentiation into groups 
of uraemic and non-uraemic animals would be useful to better clarify the situation. 
 
4.1.3 PLE 
Dogs with PLE also had higher u11-dTXB:Cr than normal dogs in this study. Again, while this 
thromboxane may be from various sources, the hypothesis was that increased levels would lead to 
increased platelet activation, and so a higher risk of thrombus formation. Other than this current study, 
to the authors knowledge there have been no previous studies looking specifically at the role of 
platelet activation in canine PLE. The only prospective study evaluating TEG in canine PLE did not 
specifically evaluate the contribution of platelet factors, as has been done by some authors for canine 
IMHA (Goodwin et al., 2011; Hamzianpour and Chan, 2016). In the human field, there is evidence that 
increased platelet reactivity plays a role in thromboembolism in both Crohn’s disease and IBD. Studies 
have found evidence of increased platelet surface expression of P-selectin, GP53 and CD40, all of 
which are prothrombotic, and increased serum levels of β-thromboglobulin, CD40 and platelet factor 
4, which are released only by activated platelets (Danese et al., 2004; Senchenkova et al., 2015). It has 
also been shown that human IBD patients have higher u11-dTXB:Cr levels than healthy controls, and 
patients with active disease have higher levels than IBD patients in remission. Interestingly the 
magnitude of the increase in u11-dTXB:Cr seen in the IBD patients in the human study (median 0.76 
ng/mg crea, IQR 0.49-1.34) is very similar to that seen in the PLE dogs in this present study (Di Sabatino 
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et al., 2016). Although this study only had a small population of dogs, the finding of increased u11-
dTXB:Cr is in agreement with findings in the human field, and suggests that increased platelet 
activation is likewise important in the pathogenesis of PLE in canine patients. Whether this increase 
in u11-dTXB:Cr correlates with an increased risk of thrombosis remains to be determined. 
Like with the IMHA dogs, the source of this thromboxane was not specifically investigated in this study, 
but is likely multifactorial, coming from activated platelets, inflammatory cells, and endothelial cells. 
In humans, immunostaining of colonic biopsy samples from people with IBD showed increased 
thromboxane synthase levels in the lamina propria layer compared to healthy controls. They also 
found higher staining in those patients with active disease than in those with inactive disease, which 
suggests the gut may be the source of the higher u11-dTXB:Cr seen in the previous human study (Carty 
et al., 2002). Thromboxane synthase staining was increased both in the lamina propria macrophages, 
and in other cell types, speculated to be lymphocytes or epithelial cells. It has been suggested that 
increased thromboxane levels within the GI microcirculation play a role in the pathogenesis of IBD, by 
promoting formation of microvascular thrombosis within the gut wall, leading to micro-infarction and 
promoting inflammation (Dhillon et al., 1992; Rampton and Collins, 1993) . As such, thromboxane 
synthase inhibitors have also been investigated as therapeutics for IBD and Crohn’s disease and have 
shown promising results decreasing urinary thromboxane levels and disease activity in some, but not 
all, initial in vivo and in vitro studies (Casellas et al., 1995; Howes et al., 2007; Tytgat et al., 2002). 
Should thromboxane production also be increased in a wider population of dogs with PLE or IBD, and 
be similarly increased locally within the GI tract, this may also represent a novel therapeutic target 
both for disease severity within the gut, as well as for systemic thrombosis risk modulation. A 
limitation of this present study is that no correlations between u11-dTXB:Cr and markers of disease 
severity such as as CIBDAI or CCECAI were performed. As such whether the dogs with the highest u11-
dTXB:Cr had the highest disease activity, as is the case in people with IBD is unknown (Di Sabatino et 
al., 2016). 
Overall, further studies looking at u11-dTXB:Cr in a wider population of dogs with PLE and IBD, ideally 
alongside measures of GI thromboxane synthesis and disease activity scores such as CIBDAI or CCECAI, 
would be interesting. It may also be possible to further investigate whether u11-dTXB:Cr can predict 
thrombosis in a larger study population. To the authors knowledge, at present there are no studies in 
people investigating whether higher u11-dTXB:Cr correlates with clinical incidence of thrombosis. 
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4.2 Serial measures in IMHA 
The final part of this study was measuring u11-dTXB:Cr over time in the surviving dogs with IMHA. The 
key finding was that median u11-dTXB:Cr was still significantly higher for the surviving dogs as a group 
than for the healthy control dogs at all time points up to 6 weeks into treatment. Additionally, at each 
time point, the majority of individual surviving dogs had u11-dTXB:Cr that was higher than the highest 
normal dog value (1.32ng/mg crea). This suggests that there is still a drive for platelet activation in at 
least some patients with IMHA by week 6 of treatment. This may mean the risk period for thrombosis 
extends for longer than the period of acute illness. At present, while antithrombotic therapy is 
considered part of the standard of care for dogs with IMHA, there is no consensus as to how long this 
therapy should be continued (Blais et al., 2019; Swann et al., 2019). At present ACVIM guidelines 
suggest thromboprophylaxis for at least the first two weeks following diagnosis, and for as long as the 
dog is receiving prednisolone. However there is only a very limited evidence base behind this 
suggestion. In humans with autoimmune anaemia, the risk of VTE has been found to be high for the 
entire first 3 months following diagnosis (Audia et al., 2018; Yusuf et al., 2015). The finding in the 
present study that some dogs still have increased u11-dTXB:Cr by as late as day 43 of treatment adds 
support to the hypothesis that some dogs will still have increased thrombotic risk beyond the initial 
two week period.  
A complicating factor in interpreting the serial u11-dTXB:Cr results is the impact of medications. Unlike 
at baseline, where patients had received very limited therapeutics prior to presentation, the dogs 
were on a wide variety of medications at the time of recheck examinations. All the dogs were receiving 
glucocorticoids and clopidogrel, at a range of dosages, and three were additionally on ciclosporine. 
Other prescribed medications included omeprazole, antibiotics for secondary urinary and GI infections, 
and faecal binding agents amongst others. Of these, ciclosporine and glucocorticoids have both been 
found to increase u11-dTXB:Cr levels in healthy dogs (Thomason et al., 2018). As such it is possible 
that the persistent increases in u11-dTXB:Cr are due to medication effects, rather than being due to 
the underlying disease. Conversely, some anti-platelet drugs are well known to reduce thromboxane 
production by platelets. Aspirin does this via direct inhibition of cyclooxygenase, and has been shown 
to reduce u11-dTXB:Cr in healthy dogs at a variety of dosages (McLewee et al., 2018; Thomason et al., 
2016). Mechanistically, clopidogrel might not be expected to affect thromboxane production, as it acts 
via surface P2Y12 receptor antagonism rather than through direct COX inhibition, and there are 
multiple alternative platelet activation pathways besides that of P2Y12 that can lead to induction of 
COX activity and so thromboxane production. Although at present there are no veterinary studies 
assessing the impact of clopidogrel on u11-dTXB:Cr, studies in healthy people showed that clopidogrel 
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can cause a similar reduction in u11-dTXB:Cr to aspirin (Armstrong et al., 2010). Thus overall it could 
be expected that the varying medications the dogs in this study were receiving might have a range of 
different impacts on their overall thromboxane production. Whether medication-induced increases in 
thromboxane alone would lead to a prothrombotic state and increase the risk of thrombosis is 
unknown, however there is a body of evidence showing that high-dose prednisolone is prothrombotic 
(van Zaane et al., 2010).  As argued previously, however, high thromboxane would be expected to lead 
to increased platelet activation, irrespective of the source. Given the risk of thrombosis in individual 
patients will be due to a combination of effects of the underlying disease, plus any prothrombotic and 
anti-thrombotic medications being given, it may be a strength of u11-dTXB:Cr as a biomarker that it is 
also affected by all of these factors. Exemplifying this, in the human field, u11-dTXB:Cr has been found 
to correlate with the ongoing risk of thrombosis in patients already on aspirin anti-thrombotic therapy 
following a previous acute coronary event (Eikelboom et al., 2002). As such the sustained increase in 
u11-dTXB:Cr found in dogs in this study is interesting, and warrants further investigation.  
4.3 Limitations 
As with all clinical research, there were a number of limitations to this study. Some of these, such as 
the difficulty in detecting thrombosis in the IMHA dogs, have already been expanded on in the relevant 
sections above. For both the PLE and PLN baseline measures, the aim was to recruit more than seven 
and eight dogs respectively, but there were fewer cases of each disease presented to the clinic during 
the study period than had been anticipated. Additionally, cases were often only identified as having 
these diseases on receipt of test results returned after the dogs had left the clinic, which meant the 
opportunity for recruitment and urine sample collection had been missed. In a number of cases further 
follow-up or dispensing of medications was performed by the referring veterinary surgeon, due to 
geographical distance from the hospital so there was also no opportunity to collect urine samples at 
a later date. These limitations were unavoidable given the nature of referral practice, but it did mean 
the case numbers for both PLE and PLN were smaller than had been hoped. For PLN this small sample 
size may have contributed to this study not finding a significant difference in baseline u11-dTXB:Cr 
from that of normal dogs. Being a referral centre may have also skewed the population of IMHA dogs 
included in this study towards those patients requiring more intensive care, so it must also be borne 
in mind that the finding of increased u11-dTXB:Cr may not hold true in less severely affected IMHA 
dogs.  
An additional limitation was that while u11-dTXB:Cr was measured in a population of healthy dogs of 
similar size to the IMHA population, this study did not set out to quantify a normal reference range 
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for canine u11-dTXB:Cr. According to current ASVCP guidelines, an ideal population size of at least 120 
individuals is needed for reliable calculation of a reference interval. Populations of as low as 20 
samples can also be used under specific circumstances, however wider 90% confidence intervals 
around the reference limits must be used, and additional samples must be collected if the CI exceeds 
0.2 times the calculated reference interval. As such this population of 16 healthy dogs (reduced to 15 
after removal of an outlier), would not be appropriate for generation of a reference interval (Friedrichs 
et al., 2012). The range of thromboxane seen in the healthy dogs was, however, very similar to that 
seen in other studies of healthy dogs where the unit u11-dTXB:Cr was measured in was reported. In 
the biggest study including 20 healthy dogs, the median u11-dTXB:Cr was 0.38 ng/mg crea, with a 
range of 0.15-1.13 ng/mg crea (Hoh et al., 2011).  However further work to recruit additional healthy 
dogs and measure u11-dTXB:Cr in another 20-30 animals (to allow for outliers) would be worthwhile. 
This would also help to better clarify the relevance of the u11-dTXB:Cr in individual animals. In all 3 
diseases there was an overlap between the range of u11-dTXB:Cr in diseased and healthy individuals. 
This may suggest that not all animals with these diseases have equal degrees of platelet activation, 
and so are not all at equal risk of thrombosis. While the ideal situation would be to have a clinical cut-
off above which the risk of thrombosis is considered significant, establishing which animals have any 
degree of increased risk would be a useful first step.  
The final limitation to this work that ought to be highlighted, is that it was not possible to assess other 
markers of platelet activation or prothrombotic phenotype in conjunction with u11-dTXB:Cr. It was 
expected that a larger proportion of clinicians would measure D-dimers in IMHA patients at baseline 
than transpired to be true, meaning it was not possible to look for any correlation with u11-dTXB:Cr. 
Equally, while a number of studies have identified both hyper- and hypo-coagulability in IMHA using 
viscoelastic tests such as TEG, and these machines are increasingly available in referral institutions, 
this methodology was not available for this study. Given this study has identified increased u11-
dTXB:Cr both at baseline and over the first 6 weeks of treatment in dogs with IMHA, investigators 
planning future studies looking at aspects of haemostasis in these patients could consider storing urine 
samples for concurrent u11-dTXB:Cr measurement.  
4.4 Final conclusions 
The studies described in this thesis have added to our knowledge of urinary thromboxanes as potential 
markers of platelet activation in dogs with three common prothrombotic conditions. While it remains 
to be seen if u11-dTXB:Cr does correlate with the clinical risk of thrombosis, this study has explored 
some difficulties surrounding accurate thrombus detection that will have to be considered in any 
85
 
future studies aiming to quantify this. The big advantage of u11-dTXB:Cr as a urine biomarker 
compared to other measures of platelet activation is that it is non-invasive to the patient to collect 
samples, and since it is stable at room temperature for up to 6 days does not rely on point-of-care 
testing or rapid transport to the laboratory. Urine markers of platelet activation also avoid the 
complications of in vitro platelet activation either during or after blood sampling that can affect blood-
based parameters such as platelet surface molecule expression. For now, u11-dTXB:Cr may represent 
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6 Appendix 1  
Supplemental tables (Appendix 1, Tables 1-4) of basic case data, baseline clinicopathological test 





Appendix 1 Table 1: Basic case data and IMHA diagnostic criteria for 20 individual dogs with primary IMHA 






















IMHA 001 Border Collie 9 19 Fe positive (macroscopic) n/a positive  positive no diagnostic 
IMHA 002 Labrador 11 31.8 Fn positive (microscopic) positive 1/64 positive  negative yes diagnostic 
IMHA 003 Springer 10 26.5 Me positive (macroscopic) positive 1/128 negative positive yes diagnostic 
IMHA 004 Cocker spaniel 5 18 Fn positive (macroscopic) positive 1/128 equivocal negative yes diagnostic 
IMHA 005 Whippet 10 10 Fe positive (macroscopic) n/a positive positive yes diagnostic 
IMHA 006 Bichon frise 6 8.6 Fe positive (microscopic) n/a positive positive yes diagnostic 
IMHA 007 Cairn terrier 12 10.7 Mn positive (macroscopic) positive 1/128 positive negative no supportive 
IMHA 008 Cocker spaniel 4 11.5 Fe positive (macroscopic) positive 1/128 positive positive yes diagnostic 
IMHA 009 Irish Setter 8 30.3 Me positive (microscopic) positive 1/128 positive positive yes diagnostic 
IMHA 010 Cross breed 5 19.9 Fn positive n/a positive positive yes diagnostic 
IMHA 011 French bulldog 6 12 Fn positive (macroscopic) n/a positive positive yes diagnostic 




12 9.9 Fn positive (macroscopic) n/a positive negative no supportive 
IMHA 014 Jack Russel 9 6.4 Fn positive (macroscopic) positive 1/128 positive positive yes diagnostic 
IMHA 015 Crossbreed 9 13.2 Fn positive (microscopic) positive 1/8 negative negative no supportive 
IMHA 017 Border Collie 10 23 Fn positive n/a positive positive yes diagnostic 
IMHA 020 Cocker spaniel 6 19.3 Fn positive (macroscopic) n/a positive positive yes diagnostic 
IMHA 021 Labradoodle 2 25 Mn positive (macroscopic) n/a positive positive yes diagnostic 
IMHA 022 Springer spaniel 5 20.5 Fn positive (macroscopic) positive 1/64 positive  positive yes diagnostic 
IMHA 023 Pomeranian 4 4 Mn positive (macroscopic) n/a positive positive yes diagnostic 
Abbreviations: IMHA, Immune mediated haemolytic anaemia, Fn, female neutered; Mn, male neutered; Me, male entire; Fe female entire 
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Appendix 1 Table 2: Selected clinicopathological data, ASA and CHAOS scores for 20 individual dogs with primary IMHA 
Study 
number 




































 IMHA 001 4 4 11.4 0.306 24.35 499 15.4 61 0  82 36 120.6 424 2.69 
 IMHA 002 3 4 19.6 0.2209 14.44 190 5 94 19 26 72 36 164.3 540 4.03 
 IMHA 003 4 6 11.6 0.061 22.94 *125 12.1 59 143 25 69 28 121.3 653 2.2 
 IMHA 004 3 1 25.5 0.1089 9.62 *125 7.8 51 59 36 76 37     1.57 
IMHA 005 3 4 19.9 0.143 35.25 401 5.8 64 16 30 65 22 152.8 718 0.97 
IMHA 006 3 2 16.2 0.199 20.17 *350 7 40 19 32 78 34 230.7 777 4.6 
IMHA 007 2 3 17 0.119 19.02 269 8.9 64 7 89 73 33 187.7 634 1.4 
IMHA 008 4 4 13.2 0.176 26.78 153 15.8 35 352 103 93 42 274 718 5.91 
IMHA 009 4 6 10.3  51.15 285 27 253 667  72 34 229.9 572 3.48 
IMHA 010 4 3 14.2 0.016 27.66 343 12.5 69 121 56 67 30   718 4.29 
IMHA 011 4 4 11.3 0.0891 14.91 *125 9.1 70 >477 217 90 40   2.8 
IMHA 012 3 7 12.3   39.55 846 12.9 53 87 36 70 28   587 1.1 
IMHA 013 3 3 22.9 0.078 13.67 333 6.1 48 4 72 82 34   8.37 
IMHA 014 4 4 19.5 0.156 15.92 *350 8.2 59 18 1321 66 27 348.1 456 1.71 
IMHA 015 3 3 14.3 0.307 25.36 *750 5.3 39 6 50 57 30 40.9 368 25.36 
IMHA 017 5 6 11       23.2 191 357 171 95 49     5.61 
IMHA 020 3 1 15.6 0.076 18.54 385 112 37 46  89 38  712 7.66 
IMHA 021 3 2 18.2 0.2071 31.09 101   60 27   73 35     5.8 
IMHA 022 4 3 17 0.116 12.75 181 16.2 113 294 2704 59 31 286.7 388 6.28 
IMHA 023 3 1 16 0.156 25.13 *350 10 62 30 237 68 31 110 616 0.83 
Abbreviations: WBC, total white blood cell count; PLT, platelet; CRP, c-reactive protein; TP, Total protein 
Notes: platelet counts marked * are estimated values based on blood smear examination comments from a clinical pathologist as follows; 'adequate' = 125, 'reference' 





Appendix 1 Table 3: Outcome data for 20 individual dogs with primary IMHA 
Study number 
Day of death 
(post diagnosis) 
Cause of death 
(IMHA vs other) 
Follow-up day last 
known alive  
(post diagnosis) 
Survival status 
at 30 days  
Survival status 
at 90 days 
Thrombus status 
 IMHA 001 6 IMHA   non-survivor non-survivor not suspected 
 IMHA 002 316 other   survivor survivor not suspected 
 IMHA 003 58 IMHA relapse   survivor non-survivor suspected 
 IMHA 004 n/a   654 survivor survivor not suspected 
IMHA 005 n/a   732 survivor survivor not suspected 
IMHA 006 11 IMHA   non-survivor non-survivor not suspected 
IMHA 007 473 other   survivor survivor not suspected 
IMHA 008 6 IMHA   non-survivor non-survivor not suspected 
IMHA 009 2 IMHA   non-survivor non-survivor not suspected 
IMHA 010 3 IMHA   non-survivor non-survivor suspected 
IMHA 011 2 IMHA   non-survivor non-survivor suspected 
IMHA 012 n/a   395 survivor survivor not suspected 
IMHA 013 n/a   319 survivor survivor not suspected 
IMHA 014 6 IMHA   non-survivor non-survivor not suspected 
IMHA 015 68 unknown   survivor non-survivor not suspected 
IMHA 017 1 IMHA   non-survivor non-survivor suspected 
IMHA 020 n/a   232 survivor survivor not suspected 
IMHA 021 120 IMHA relapse   survivor survivor not suspected 
IMHA 022 1 IMHA   non-survivor non-survivor suspected 
IMHA 023 n/a   163 survivor survivor not suspected 








Appendix 1 Table 4: Treatment information for 20 dogs with primary IMHA 
Study 
number 
Initial treatment data 
Subsequently started 
immunosuppressives 


















drug C dose 
(mg/kg/day) 
Additional 
IS drug D 
Additional IS 




IS drug D 
added 
IMHA 001 pRBC clopidogrel 2.0 dex  0.30 myco 13.2       
IMHA 002 none clopidogrel 2.4 dex 0.31 myco 7.9           









IMHA 004 pRBC clopidogrel 2.1 pred 1.94 myco 13.9           
IMHA 005 pRBC clopidogrel 3.8 pred 2.00 cyclo 5.0       
IMHA 006 pRBC clopidogrel 2.2 dex 0.23 cyclo 16.3           
IMHA 007 none clopidogrel 1.7 dex 0.30     myco 9.3 6 
IMHA 008 pRBC clopidogrel 1.6 dex 0.30 myco 10.0           
IMHA 009 pRBC clopidogrel 1.2 dex 0.30 myco 10.0       
IMHA 010 pRBC clopidogrel 1.9 dex 0.18 myco 12.1           
IMHA 011 pRBC clopidogrel 3.1 dex 0.28 aza  2.1       
IMHA 012 pRBC clopidogrel 1.5 dex 0.32 myco 8.1     cyclo 4 9 
IMHA 013 none clopidogrel 1.9 pred 2.02 myco 20.2       
IMHA 014 pRBC clopidogrel 2.0 dex 0.30 cyclo 7.8           
IMHA 015 pRBC clopidogrel 2.8 dex 0.07 myco 24.2       
IMHA 017 none clopidogrel 1.6 dex 0.52               
IMHA 020 pRBC clopidogrel 1.0 dex 0.31 myco 13.0       
IMHA 021 none clopidogrel 3.0 dex 0.50 aza  2.0           
IMHA 022 pRBC clopidogrel 1.8 dex 0.60 myco 19.5       
IMHA 023 pRBC clopidogrel 4.7 dex 0.30 cyclo 10.0           
Abbreviations: IMHA, Immune mediated haemolytic anaemia; IS, immunosuppressive; pRBC, packed red blood cells; IgG, immunoglobulin; dex, dexamethasone; pred, 
prednisolone; myco, mycophenolate; cyclo, cyclosporine; aza, azathioprine 
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